This is Vanlead Group – Enviro's Chinese partner

Guangzhou Vanlead Group is a state-owned large industrial enterprise in Guangzhou. Founded in 2001, Vanlead specializes in the fields of rubber tyre, salt chemical and fine chemical with distinct regional and industrial advantage. In the middle of June, Enviro made another visit to China to continue planning and discussing issues related to the establishment of a recycling plant in the region. “Both parties are working with great commitment to drive the process forward and the ambition to commence the project during this year remain to the highest extent”, says Thomas Sörensson. Vanlead has a large number of subsidiaries, one of them being tyre manufacturer South China Tire & Rubber Co, the first large-scale state-owned enterprise to introduce professional technology to produce full-series radial tires in China. One of South China Tire & Rubber’s brands is Wanli Tire which, with annual capacity of 16 million tires and 2,100 employees, is the largest radial tire manufacturer in Southern China and one of the largest radial tire exporters in the country. Vanlead Group’s tyre production represents a strategic area both domestically and internationally. The company is one of the world’s largest tyre manufacturers and exports tyres to Europe, the United States, and other parts of the world. Their aim is to expand production capacity, improve economy of scale, enhance competitiveness and become a domestic leading and world-famous rubber and tyre enterprise. “China is the world’s biggest tyre market and new solutions for processing end-of-service tyres more circularly are necessary from both environmental and resource-related perspectives. Vanlead wants to take the initiative in the industry,” says Thomas Sörensson. Vanlead Group recently signed a Project Investment letter of intent with the state of South Carolina to start building a $1 billion plant in South Carolina next year. The group also plans to set up a research centre in Europe and a joint research facility in Akron, Ohio. The US tyre plant will mark a major step in Vanlead's effort to build its brand globally. Environmental efficiency Vanlead's new Hefei factory, featuring so-called Industry 4.0, has been and is set up to be one of the world’s most automated tyre production units. To make the production greener, the factory has power generating facilities using steam pressure differential installed, saving close to $800,000 annually in energy costs. The factory’s water recycling system also enables the factory to achieve zero wastewater discharge. “Vanlead share Enviro’s view that our unique production technology for sustainable materials is the future for the tyre industry. The fact that a state-owned company is the first to exhibit this high level of ambition is very positive,” says Thomas Sörensson. Read more about Vanlead Group  For further information, please contact:Thomas Sörensson, CEO Enviro, tel: +46 (0)735-10 53 43, thomas.sorensson@envirosystems.se  Stig-Arne Blom, Board Chairman Enviro, tel: +46 (0)705-25 16 15, stigarne@blom.pp.se Scandinavian Enviro Systems ABRegnbågsgatan 8CSE-417 55 Gothenburginfo@envirosystems.sewww.envirosystems.se

Midweek Summer Specials for California B&Bs and Boutique Hotels

SACRAMENTO, CA [June 22, 2017]--Find great midweek deals for stays at boutique hotels and bed and breakfast inns in California this summer.  Several members of the California Association of Boutique and Breakfast Inns (CABBI) are offer discounted rates midweek, making a summer vacation to the desert, beach or wine country all the more affordable.  Several midweek lodging deals are listed below; more are available at www.cabbi.com/specials. Soak up the sun and the savings with POSH Palm Springs’  Hot Summer Savings.  The inn’s two-night packages offer up to 35% off regular rates.  With the two-night package, a weekday stay in a deluxe room is only $99 per night plus tax.  Sun worshippers will enjoy the inn’s large courtyard swimming pool, which offers many more lounge chairs than the hotel will ever have guests.  The offer is only available at the time of booking and cannot be combined with other offers, vouchers or gift certificates. Taxes are not included. Minimum two nights, maximum six nights. Blackout dates apply.  Reservations can be made online or by calling 760-992-5410. Indulge in a midweek wine tour with the Two Night Stay and Tour Wine Package from Cottage Grove Inn  in Calistoga.  The inn’s private cottages exude laid-back luxury in a tranquil, romantic setting.  The package features a two-night stay with a full breakfast and evening wine pairing each day and a group wine tour to four boutique Napa Valley wineries. The tour includes door-to-door pick-up in a luxury Mercedes Sprinter Limousine, complimentary champagne, bottled water, soft drinks, and a vineyard picnic lunch.  The tour must be booked directly with Dynamic Wine Tours.  The package is $895 plus tax, tasting fees and gratuities.  The package cannot be combined with any other offers and is not valid July 2-4, 2017.  To reserve, call 707-942-8400. Enjoy a romantic island getaway and save 25% off midweek rates this summer with Catalina Island Inn's  Exclusive Summer Special.  Guests can receive 25% off any stay Sunday through Thursday night in July or August if booked with a one-night deposit prior to June 30, 2017.  The inn is also offering some of its best rooms at a great discount through the summer months.  Call the hotel for details at 800-246-8134. The newly remodeled boutique hotel is located just a half block from the beach, dining, shops and tours. Linger longer in Napa Valley with La Belle Epoque Bed & Breakfast Inn’s  Midweek Special.  Now through the end of July, guests can stay two nights and get the third night 50% off.  The inn is an elegant, turn-of-the-century, Queen Anne Victorian located in Napa Valley that offers exquisite accommodations, fine amenities and impeccable guest services. The inn is known for its three-course gourmet breakfasts and formal afternoon teas. The midweek special is valid for consecutive, three-night stays Sunday through Thursday only through July 31, 2017.  Call 707-257-2161 to make a reservation. Play hooky this summer in Sonoma wine country at the Farmhouse Inn  and save 20% off the inn’s best available rates for midweek stays.  This luxurious boutique hotel near Healdsburg was recently ranked as the number-one hotel in California by readers of Travel + Leisure. Date night never tasted better with the inn’s on-site Michelin-starred restaurant, farm-to-table spa, and the region’s best concierge team. Guests can also cozy up to their in-room, wood-burning fireplaces and enjoy s’mores around the firepit. The Play Hooky Midweek special is valid Sunday through Thursday nights.  To make a reservation, call 707-887-3300. Enjoy a Balinese-inspired escape to San Diego and save 15% with Pantai Inn’s  Summer Midweek Getaway special.  Overlooking La Jolla’s scenic coastline, the boutique hotel masterfully blends Bali’s old-world charm and kingly comforts with modern amenities. Offer is valid for stays through September 4, 2017, and is subject to availability. Blackout dates may apply. The special is not valid for existing reservations and may not be combined with any other offers. To reserve, book online  using the promo code CABBI or call 858-224-7660. Enjoy a dreamy summer getaway to Napa and save 10% midweek with the Inn on Randolph’s  Midsummer Night’s Dream Special.  The hip and luxurious inn combines the intimacy of a bed and breakfast with the elegance and amenities of a boutique hotel.  The 10% savings is valid for Sunday through Wednesday night stays of two or more nights through August 31, 2017.  The special is valid for new reservations only. Rates are subject to availability; blackout dates apply.  May not be combined with any other special offer or discount. To reserve call 707-257-2886 or use code MIDWEEK to book online. Enjoy solitude and sultry summer nights in the desert with The Chateau at Lake La Quinta’s  Desert Nights package.  The chic boutique hotel sits beside a shimmering lake and offers 24 newly-renovated rooms, attentive service and a new lakeside restaurant serving breakfast, lunch and dinner. With midweek rates starting at $199 plus tax, the Desert Nights package includes the daily resort fee (a $25 value) and $50 resort credit.  The package is valid Sunday through Thursday through September 28, 2017 and is based on availability. Call 760-564-7332 to make a reservation. Get a free upgrade to a more expensive room when booking Courtwood Inn’s  Run of the House midweek special.  The newly-constructed cedar log B&B features luxurious amenities, beautiful Sierra Foothills views and is just minutes from downtown Murphys’ wine tasting rooms, boutiques and cafes.  The special is available Sunday through Thursday nights for guests booking the Davis Cup room.  The upgrade is not available for guests traveling with pets. Blackout dates and other restrictions apply.  Use promo code “Run of the House” when booking online or call 209-728-8686. Escape to Catalina Island with Hotel Catalina’s  Summer Paradise Package. Quietly nestled a few doors from Avalon Bay, Hotel Catalina offers the charm and hospitality of yesteryear with all the modern amenities of today. The package includes a one-night midweek stay in a standard room with a queen bed, roundtrip boat transportation on Catalina Express, and discounts on local dining and tours.  Package rates start at $131 per person per night midweek. Rates are based on double occupancy and exclude tax. Additional nights and upgrades are available. The package is valid Sunday through Thursday nights through October 19, 2017. To reserve, call 800-540-0184. Book a three-night midweek getaway in Paso Robles’ wine country and enjoy additional perks courtesy of Orchard Hill Farm .  The three-night stay at the inn includes a cheese plate and bottle of wine upon arrival, a picnic lunch with personal wine touring recommendations, a choice of two wine tours, and complimentary tasting tickets.  Built in the style of a traditional English country house, the three-room inn is a hilltop retreat with views of the neighboring vine yards and valley. To reserve the midweek special, call 805-239-9680 and mention CABBI.  For more information about these and other specials at California inns, visit www.cabbi.com/specials. ### Media Contact: Ranee Ruble, ranee@papermooncreative.net or 503-788-3938  

Saab receives Self-Protection Systems order for H225M Caracal helicopters

Saab’s Integrated Defensive Aids Suite (IDAS) protects the crew by enhancing platform survivability in sophisticated, diverse and dense threat environments. The system provides timely warning against radar, laser and infrared (IR) guided threats and automatically deploys the appropriate countermeasures. “This order confirms Saab´s strong position as a supplier of world class airborne self-protection systems, which improves the customer’s operational capabilities,” says Anders Carp, head of Saab business area Surveillance. Production of the IDAS self-protection system will take place in 2017- 2018 at Saab Grintek Defence premises in Centurion, South Africa, with deliveries scheduled for 2020. “Saab has a longstanding relationship with Airbus and the order of our effective and reliable IDAS system reaffirms our partnership,” says Trevor Raman, CEO of Saab Grintek Defence. The system has a long and successful history with proven capability on many airborne platforms such as the Saab 2000, Agusta-Westland A109, Super Lynx 300, Boeing CH-47 Chinook, Denel Rooivalk and Oryx, Eurocopter Cougar, Puma and Super Puma, NH Industries NH90, C-130 and L100 Hercules, Sukhoi Su-30MKM. Deliveries are ongoing for the HAL Advanced Light Helicopter Dhruv. For further information, please contact: Saab Press Centre, +46 (0)734 180 018 presscentre@saabgroup.com www.saabgroup.com  www.saabgroup.com/YouTube  Follow us on twitter: @saab  Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs. 

Asetek announces new data center order to cool NVIDIA’s P100 GPU accelerators

Aalborg, Denmark, 23 June 2017 – Asetek today announced a new order from Penguin Computing, Asetek’s longstanding OEM partner for a new undisclosed HPC (High Performance Computing) installation.  Asetek’s proprietary Direct-to-Chip (D2C) liquid cooling technology was selected by Penguin Computing to cool NVIDIA’s P100 GPU accelerators, the most advanced GPUs yet produced by NVIDIA.  “Utilizing Penguin's Tundra ES platform with Asetek's D2C liquid cooling technology will allow our government clients to push the boundaries of these GPU's for deep learning research,” said Ken Gudenrath, Director, Federal Division, Penguin Computing. “Asetek has been chosen to cool the world’s most advanced GPUs. It is an important validation of our offering and we are pleased that our OEM partner, Penguin Computing, continues to select Asetek technology. This is an initial order, and we expect additional deliveries to follow,” said André Sloth Eriksen, CEO and founder of Asetek. Asetek signed a global purchasing agreement  with Penguin Computing in 2015. This initial order is for 140 loops to be used with Asetek’s RackCDU Direct-to-Chip (D2C) liquid cooling solution and have a value of USD 40,000 with delivery in August 2017. About AsetekAsetek is the global leader in liquid cooling solutions for data centers, servers and PCs. Founded in 2000, Asetek is headquartered in Denmark and has operations in California, Texas, China and Taiwan. Asetek is listed on the Oslo Stock Exchange (ASETEK). For more information, visit www.asetek.com For further information, please contact:André S. Eriksen, Chief Executive OfficerMobile: +45 2125 7076, e-mail: ceo@asetek.com

Major League Baseball Players Alumni Association Brings Legends for Youth Baseball Clinic Series to Cincinnati, OH

Colorado Springs, Colo. – Local youth will have an opportunity to play with their big league heroes at the Major League Baseball Players Alumni Association (MLBPAA) Legends for Youth baseball clinic series on Monday, June 26th, 2017. In conjunction with the Cincinnati Urban Youth Academy , the free clinic features former Major League Baseball players who will teach baseball skills, drills and life lessons for approximately 200 local youth. Players attending* include 1990 Cincinnati Reds World Series champion Tom Browning, as well as Joe Cowley, Bill Earley, Chris Nichting, Denny O’Toole, Steve Stemle and Kip Young. These seven players combine for 31 seasons, 165 wins and 545 games in Major League Baseball. The clinic will take place at P&G Cincinnati MLB Urban Youth Academy, running from 10:00 a.m. to 12:00 p.m., located at 2026 E Seymour Avenue, Cincinnati, OH 45237. Alumni players will train at stations including pitching, catching, base running and life skills. Registration will begin at 9:30 a.m. and the morning will conclude with an autograph session and baseball giveaways for children in attendance. Registration is closed to the public at this time. For more information regarding the clinic, please contact Nikki Warner, Director of Communications, at (719) 477-1870, ext. 105 or visit www.baseballalumni.com. *Clinicians subject to change. About The Major League Baseball Players Alumni Association (MLBPAA) MLBPAA was founded in 1982 with the mission of promoting baseball, raising money for charity and protecting the dignity of the game through its Alumni players. The MLBPAA is headquartered in Colorado Springs, CO with a membership of more than 7,800, of which approximately 6,100 are Alumni and active players. Alumni players find the MLBPAA to be a vital tool to become involved in charity and community philanthropy. Follow @MLBPAA for Twitter and Instagram updates.   About Legends for Youth Clinics MLBPAA’s Legends for Youth clinics impact more than 16,000 children each year, allowing them the unique opportunity to interact with and learn from players who have left a lasting impact on the game of baseball. The MLBPAA has reached children across America and internationally in Australia, Canada, China, Curaçao, the Dominican Republic, Germany, Italy, New Zealand, Nicaragua, the United Kingdom and Venezuela, through the Legends for Youth clinic series. To donate to this program, visit baseballalumni.com/donate . The official hashtag of the Legends for Youth clinic series is #LFYClinic.   ###

Investigation by the Brazilian Administrative Council for Economic Defense comprises two Getinge entities

Two of Getinge’s entities in Brazil, Maquet Cardiopulmonary do Brasil Indústria e Comércio Ltda and Maquet do Brasil Equipamentos Médicos Ltda, and employees within these companies are being investigated by the Brazilian General Superintendence of the Administrative Council for Economic Defense (CADE) regarding alleged cartel activities. The investigation is part of ongoing public investigations on cartel activities related to the sales of medical equipment and is being carried out by the Brazilian authorities. According to a press release issued by CADE, 46 companies, 80 individuals and the industry association Associação Brasileira de Importadores e Distribuidores de Implantes (ABRAIDI) are under investigation. Potential consequences for Getinge are not yet known and too early to comment upon. Media contacts: Jeanette Hedén Carlsson,EVP Communications & Brand ManagementPhone: +46 (0)10 335 1003Email: jeanette.hedencarlsson@getinge.com Anna Appelqvist,Head of Media RelationsPhone: +46 (0)10 335 5906Email: anna.appelqvist@getinge.com This information is information that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11:00 CEST on June 24, 2017. About GetingeGetinge is a global provider of innovative solutions for operating rooms, intensive care units, sterilization departments and for life science companies and institutions. Based on our firsthand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving the everyday life for people - today and tomorrow.  

EQT VII to invest in global “hidden champion” and medical mobility technology market leader Ottobock

· EQT VII to acquire a 20% stake in Germany-based Ottobock, the global market leader in medical mobility solutions ranging from prosthetic and orthotic products to wheelchairs and accompanying services · Founded by Otto Bock in 1919, the Company has been an industry innovator and has launched the first completely microprocessor-controlled lower limb prosthesis, among others · EQT will support majority owner Professor Hans Georg Näder and the management team on Ottobock’s continued growth trajectory and focus on innovation The EQT VII Fund (“EQT VII”) has entered in to an agreement to acquire a 20% stake in Ottobock (or “the Company”) from Otto Bock HealthCare GmbH. Since its foundation in 1919 by Otto Bock, the Company has been a synonym for revolutionizing, innovating and moving forward medical mobility technology. Otto Bock started the first serial production of prosthetic components post World War I. After World War II, the Company introduced the modular solution for upper and lower limb prosthesis. In 1997, Ottobock launched the C-Leg, the world's first completely microprocessor-controlled lower limb prosthesis solution. Over nearly a century, Ottobock’s products have allowed users to achieve a better quality of life, more mobility and independence. True to this philosophy, Ottobock has actively supported the Paralympic Games since 1988 and has been a partner of the International Paralympic Committee since 2005. Ottobock is headquartered in Duderstadt, Germany and operates subsidiaries in more than 50 countries with more than 7,000 employees worldwide. In 2016, the Company generated more than EUR 880 million in sales and EQT valued the Company at EUR 3.15 billion. “I am very pleased to take EQT on board as a partner who shares the values of a family-backed company given its Wallenberg background. EQT also has a track record of sustainable value creation and growth”, says Professor Hans Georg Näder, majority shareholder and grandson of the company founder. “I am convinced that EQT’s experience in developing companies will allow us to continue Ottobock’s success story well beyond the Company’s 100th birthday”, concludes Professor Näder. “We are impressed by Ottobock’s long heritage of innovation and its ability to define the landscape of mobility solutions in the area of wearable home rehabilitation regarding the growing market of human bionics. Based on EQT’s deep healthcare expertise, and as one of the most active investors in the sector, we will be a strategic partner to Professor Näder, the management and the Company. We look forward to working together and contributing to the continued success of Ottobock”, added Marcus Brennecke, Partner at EQT Partners and Investment Advisor to EQT VII. The transaction is subject to approval by the relevant competition authorities and is expected to close in the second half of 2017. Contacts: Marcus Brennecke, Partner at EQT Partners, Investment Advisor to EQT VII, +49 89 255499 20 EQT Press office, +46 8 506 55 334 About EQT EQT is a leading alternative investments firm with approximately EUR 37 billion in raised capital across 24 funds. EQT funds have portfolio companies in Europe, Asia and the US with total sales of more than EUR 19 billion and approximately 110,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. More info: www.eqtpartners.com About Ottobock Ottobock develops medical technology products and fitting concepts for people with limited mobility in the fields of Prosthetics, Orthotics, Human Mobility (wheelchairs, rehabilitation devices) and MedicalCare. Subsidiaries in over 50 countries offer quality “Made in Germany” worldwide and employ more than 7,000 people. Ottobock has been a family-managed company since its founding in 1919 and has also been supporting the Paralympic Games with its technical know-how since 1988. More info: www.ottobock.com  

Cleantech Invest portfolio firm Nuuka Solutions Lands in California

Cleantech Invest portfolio company Nuuka Solutions has established a subsidiary company in Los Angeles, CA. The Californian subsidiary will be a joint effort between Nuuka and Ms. Marylou Garcia who will be spearheading the efforts to bring yet another Nordic technology to American shores. Cleantech Invest owns 34% of Nuuka. Nuuka, who will own 51% of the Joint Venture, is a data software and platform company operating in the rapidly developing smart building sector. They have realized significant growth in the first two quarters of 2017 and are poised to continue this growth into the second half of the year. California is leading the United states in Cleantech adoption, and businesses such as Nuuka continue to see the greater Los Angeles area as one of the key markets to tackle if they want to become a leading player in the cleantech movement. Nuuka is doing their part by making smarter and sustainable buildings a reality in the United States. Marylou Garcia, CEO and President of Nuuka Inc., has an MBA from Wharton and is well established in the California market. She is also the Managing Director for Expense Reduction Analysts, Los Angeles – an enterprise that helps organizations put additional cash flow to work by further lowering supplier costs, without any compromise to quality and service. Through partners and alliances, Nuuka Inc will be able to reach thousands of potentials customers in the United States. Nuuka CEO, Mikko Valtonen: “We have had a very busy first 2 quarters of 2017. We have been successful in getting key new customers to use our software both here in the Nordics, and abroad in Benelux and the US. We see the opening of a subsidiary in California as a logical next step on our growth journey to becoming one of the key players in this rapidly developing smart building market. We are very excited about the partnership we now have with Marylou Garcia and her extensive networks. We look forward to starting projects in California in the very near future” Cleantech Invest Chairman of the Board, Lassi Noponen based in Los Angeles: “Cleantech Invest combines the best Nordic cleantech with formidable American entrepreneurship by bringing a set of its portfolio companies to the US and Nuuka is first project to go live. We have several other projects in progress and hope to be able to announce the next company very soon. Nordic Cleantech is very competitive on the global stage, as Finland and Sweden continue to act as the epicenter for technological innovation. There is tremendous market potential to bring these technologies to the US.” Consul General of Finland in Los Angeles, Stefan Lindström: “California and the Nordics are leaders in clean technologies. We are here to support Finnish companies’ entry to the massive US market and have been happy to contribute to Cleantech Invest’s and progress in California. Innovators like Nuuka are important pioneers and will pave way for many more Nordic cleantech companies’ emergence to the US market.” Cleantech Invest CEO, Alexander Lidgren: “We set up our office in California to help our companies grow in the USA. I don’t think Lassi could have found a better partner for Nuuka than Marylou Garcia. Nuuka has a scalable solution that real estate owners in the Nordics love, and I am really exited to see how it will be received in the American market.” Marylou Garcia, CEO and President of Nuuka Inc: “As buildings continue to get smarter and generate massive amounts of data, Nuuka provides a cost efficient solution to allow property owners, developers and managers real-time, instantaneous visibility to all their automation systems for quick decision and action. Nuuka combines sustainability, energy efficiency and customer satisfaction under one platform. California has historically been first to adopt and commercialize new technologies, and I am looking forward to begin working with Nuuka solutions in continuing to make that statement true.”

BerGenBio Awarded NOK 24m from Innovasjon Norge to Support the Clinical Development of BGB324 in Combination with KEYTRUDA® for Advanced Lung Cancer

Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “We are delighted to have received this grant award, the largest grant from the “Industrial Development” program ever made by Innovasjon Norge. BGB324 is a novel small molecule Axl inhibitor that, as a one-a-day pill, offers an exciting opportunity to treat multiple cancers through a potentially universal mechanism. Axl signalling is a central process that promotes cancer cells to become aggressive. By blocking Axl signalling, tumour cells revert to a stable state where we believe they can be targeted and destroyed by the immune system and re-sensitized to other cancer therapies. We believe therefore that BGB324 alone and in combination with immunotherapies, such as KEYTRUDA, has the potential to significantly improve the clinical outcomes in a broad range of cancers. We anticipate announcing the results of this combination Phase II study in 2018.” The grant from Innovasjon Norge is an Industrial Development Award (IFU). The IFU program is directed to Norwegian companies developing new products or services in collaboration with foreign companies. The NOK 24 million grant will contribute towards BerGenBio’s costs of running this specific Phase II clinical trial. Director Nina Broch Mathisen of Innovasjon Norge, said: ”We are pleased to have made this very significant grant award to BerGenBio. We have been very impressed by the innovation demonstrated by BerGenBio in a highly competitive global market, in an industry within our defined area of focus. The clinical data that has already been generated with BGB324, has convinced us to support the Phase II study in advanced lung cancer patients assessing BGB324 in combination with KEYTRUDA. We are optimistic that this study will contribute to value creation in Norway, positively promote the Norwegian healthcare sector, and will offer renewed hope to a large number of cancer patients.”  In March 2017, BerGenBio entered into a collaborative agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), focused on the clinical evaluation of BGB324 with KEYTRUDA® in patients with advanced non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). About BerGenBio ASA BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class Axl kinase inhibitors to treat multiple cancer indications. The Company is a world leader in understanding the essential role of Axl kinase in mediating cancer spread, immune evasion and drug resistance in multiple aggressive haematological and solid cancers. BerGenBio’s lead product, BGB324, is a selective, potent and orally bio-available small molecule Axl inhibitor in Phase II clinical development in four major cancer indications. It is the only selective Axl inhibitor in clinical development. BGB324 is being developed by BerGenBio as a single agent therapy in acute myeloid leukaemia (AML)/myeloid dysplastic syndrome (MDS). In advanced non-small-cell lung cancer (NSCLC), BGB324 is tested in combination with TARCEVA® (erlotinib) as well as TAXOTERE® (docetaxel) and KEYTRUDA® (pembrolizumab). In advanced melanoma, combination of BGB324 with either MEKINIST® (trametinib) and TAFINLAR® (dabrafenib) or KEYTRUDA® are being explored. A further combination of BGB324 with KEYTRUDA® is being tested in triple negative breast cancer (TNBC). The clinical trials combining BGB324 with KEYTRUDA® in NSCLC and TBNC are conducted in collaboration with Merck & Co. Inc. (MSD). The Company is also developing a diversified pre-clinical pipeline of drug candidates, including BGB149 an anti-Axl monoclonal antibody. For further information, please visit: www.bergenbio.com KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. TARCEVA® is a registered trademark of OSI Pharmaceuticals, LLC., marketed by Roche-Genentech.  -Ends- Contacts   Richard Godfrey  CEO, BerGenBio ASA +47 917 86 304 David Dible, Mark Swallow, Marine Perrier Citigate Dewe Rogerson bergenbio@citigatedr.co.uk +44 207 638 9571 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Lifco acquires Perfect Ceramic Dental in China

Lifco has signed an agreement to acquire the Chinese dental company Perfect Ceramic Dental (PCD). PCD is a dental laboratory that produces dentures and dental prosthetics mainly for MDH, a German Lifco subsidiary. PCD has since the 1990s produced dental crowns, bridges and complex restorations for MDH Germany. The company has its main facility in Shenzhen, China. PCD reported net sales of 118 MHKD in 2016. Approximately 80% of PCD’s sales is generated by MDH, a Lifco subsidiary in Germany, which means that the acquisition will have very limited effect on Lifco’s consolidated external sales. PCD currently has about 850 employees. The acquisition will not have any significant effect on Lifco’s earnings or financial position in current financial year. For more information please contact: Per Waldemarson Head of Business Area Dental Phone +46 70 840 00 63, E-mail per.waldemarson@lifco.se Åse Lindskog  Media and investor relations managerPhone +46 730 244 872, E-mail ir@lifco.se About Lifco Lifco acquires and develops market-leading niched operations with the potential to deliver sustainable profit growth and strong cash flows. The Group has three business areas: Dental, Demolition & Tools and Systems Solutions. Lifco has a clear corporate philosophy which implies a long-term perspective, focus on profits and a highly decentralized organization. Lifco has 133 companies in 26 countries. In 2016, the Group’s net sales amounted to SEK 9 billion and the EBITA margin was 15%. For more information, visit www.lifco.se.

Enquest Plc Announces Kraken First Oil

26 June 2017     EnQuest confirms that first oil from the Kraken development was delivered on 23 June 2017.  During the initial ramp-up period, the 13 wells that have been drilled and completed to date, comprising 7 producers and 6 injectors, are being brought online in a phased manner, to maximise long term productivity and value.   EnQuest CEO, Amjad Bseisu said:"EnQuest is delighted to confirm that first oil has been achieved on the Kraken development, delivered on schedule and under budget.  Drill centres 1 and 2 are fully complete and work continues on drill centre 3; as a result, further production capacity will come online into 2018 as these further wells are put onstream.  Kraken is a transformational project, made possible by EnQuest's differential capabilities; the right mix of integrated technical capabilities, high levels of efficiency and cost discipline. With production from Kraken, EnQuest is moving from a period of heavy capital investment, to a focus on cash generation and deleveraging the balance sheet.  A further update and additional analysis will be provided with EnQuest's 2017 half year results." EnQuest's Head of Major Projects, Richard Hall said:"The achievement of producing first oil from Kraken on schedule and considerably under budget is a great testament to the capabilities of EnQuest. I am extremely proud of the EnQuest Kraken team for their dedication, vison and sheer hard work and thank them for this exceptional performance. Our approach of rigorous planning, simplification of specifications and clarity in execution methodology has enabled us successfully to deliver this highly complex project."  UK Business and Energy Secretary Greg Clark said:"This is a landmark project for EnQuest and the UK oil and gas sector as one of the largest new oil fields to come on-stream in the North Sea in a decade. This has been made possible through significant UK government support to encourage investments of this type in the North Sea, supporting thousands of highly-skilled jobs.      We'll continue to build on this support for the oil and gas sector as it looks to seize the significant opportunities that lie ahead."   UK Oil & Gas Authority Chief Executive, Dr Andy Samuel said: "As one of the most significant oil field projects in the UK Continental Shelf, successful production from Kraken is positive news for the whole basin. It has the potential to open up additional heavy oil opportunities in the Northern North Sea, with other developments in the pipeline. It's particularly pleasing to see a project delivered under budget, having clearly benefitted from a strong partnership between operator and key service providers."     Ends  For further information please contact: +-----------------------------------------------+--------------------------+|EnQuest   PLC |Tel:   +44 (0)20 7925 4900|+-----------------------------------------------+--------------------------+|Amjad Bseisu | ||(Chief Executive) | |+-----------------------------------------------+--------------------------+|Jonathan Swinney | ||(Chief Financial Officer)  | |+-----------------------------------------------+--------------------------+|Michael Waring | ||(Head of Communications & Investor Relations)  | |+-----------------------------------------------+--------------------------+|Tulchan Communications |Tel:   +44 (0)20 7353 4200|+-----------------------------------------------+--------------------------+|Martin Robinson | |+-----------------------------------------------+--------------------------+|Martin Pengelley  | |+-----------------------------------------------+--------------------------+ Notes to editors  This announcement has been determined to contain inside information.  THE KRAKEN DEVELOPMENT: Facts and figures  · Kraken is a large heavy oil accumulation in the UK North Sea, located in the East Shetland basin, to the west of the North Viking Graben, approximately 125 km east of the Shetland Islands  · The field contains c.128 MMboe of gross 2P reserves, making it one of the largest new oil fields to come onstream in the North Sea since Buzzard   · Gross peak oil production expected to be approximately 50,000 barrels of oil per day  · The gross capital costs of the development are currently estimated to be approximately $2.5 billion, down from $3.2 billion at the time the project was sanctioned; good planning and project execution including good progress on drilling and on the execution of the subsea programme were key factors in the capex savings.  Drilling and formation evaluation have shown excellent correlation with pre-sanction subsurface expectations  · EnQuest has an interest of 70.5% in Kraken, with its partner in the development Cairn Energy PLC having the balancing 29.5%  · Kraken is EnQuest's seventh operated production hub  · At the time the development was sanctioned, using Oil and Gas UK's reporting metrics it was estimated that the development would support more than 20,000 UK jobs during the construction period of the project and an average of approximately 1,000 operational jobs in the UK for each year of the Kraken field's life of over 20 years  · The Kraken FPSO vessel has the largest liquid handling capacity in the UKCS  · Other field details: Field area ~ 12 x 3.5 km: Water depth of c.110m     ENQUESTEnQuest is one of the largest UK independent producers in the UK North Sea.  EnQuest PLC trades on both the London Stock Exchange and the NASDAQ OMX Stockholm. Its operated assets include Thistle/Deveron, Heather/ Broom, the Dons area, the Greater Kittiwake Area, Scolty/Crathes and Alma/Galia, also the Kraken development; EnQuest also has an interest in the non-operated Alba producing oil field.  At the end of December 2016, EnQuest had interests in 25 UK production licences, covering 35 blocks or part blocks and was the operator of 23 of these licences.  EnQuest believes that the UKCS represents a significant hydrocarbon basin, which continues to benefit from an extensive installed infrastructure base and skilled labour.  EnQuest believes that its assets offer material organic growth opportunities, driven by exploitation of current infrastructure on the UKCS and the development of low risk near field opportunities.   EnQuest is replicating its model in the UKCS by targeting previously underdeveloped assets in a small number of other maturing regions; complementing its operations and utilising its deep skills in the UK North Sea.  In which context, EnQuest has interests in Malaysia where its operated assets include the PM8/Seligi Production Sharing Contract and the Tanjong Baram Risk Services Contract.   Forward looking statements: This announcement may contain certain forward-looking statements with respect to EnQuest's expectation and plans, strategy, management's objectives, future performance, production, reserves, costs, revenues and other trend information.  These statements and forecasts involve risk and uncertainty because they relate to events and depend upon circumstances that may occur in the future.  There are a number of factors which could cause actual results or developments to differ materially from those expressed or implied by these forward looking statements and forecasts.   The statements have been made with reference to forecast price changes, economic conditions and the current regulatory environment.  Nothing in this presentation should be construed as a profit forecast.  Past share performance cannot be relied on as a guide to future performance.     Glossary     DC       Drill centreESP     Electrical submersible pumpFPSO  Floating production, storage and offloading vessel  This information is provided by RNSThe company news service from the London Stock Exchange END

DIGNITANA MEDICAL ADVISORS HELP LAUNCH INTERNATIONAL SCALP COOLING COLLABORATION AMONG TOP CANCER CENTERS WORLDWIDE

Lund, Sweden – June 26, 2017 – Dignitana AB, a world leader in medical scalp-cooling technology and manufacturer of the DigniCap® scalp cooling system, is partnering with the organization known as CHILL, Cancer-related Hair Loss, International Leadership and Linkage, which was launched this past weekend at the 2017 Annual Meeting of the Multinational Association of Supportive Care in Cancer (MASCC),  held in Washington, D.C. Led by six globally-recognized experts in cancer care, CHILL is an initiative designed to collect and track evidence-based patient information and provide clinical guidance for health practitioners and patients using scalp cooling medical devices that reduce hair loss for patients receiving chemotherapeutic cancer treatments. Data collected through the initiative will help establish industry-standard best practices and ensure maximum effectiveness of these treatments worldwide. A new website, scalpcooling.org , will serve as a global hub for patients and care providers seeking information about hair loss and scalp cooling technology, as well as a decision aid with data from the CHILL registry showing chances of hair loss with and without scalp cooling. With an estimated 14.1 million patients diagnosed with cancer worldwide in 2012 (according to World Cancer Research Fund International ), cancer is a significant global health issue affecting every region and socioeconomic group. The CHILL Registry strives to become a platform that allows clinicians to understand cancer-related hair loss during leading edge cancer therapies, improve supportive care by comparing their own data with international estimates, and access the extensive resources of comprehensive cancer treatment teams around the world. “At Dignitana, we take pride in our ability to be a leader of innovation and remain on the cutting edge of technological developments that help us provide the best possible care and outcomes for our patients,” said Johan Ericsson, Chief Executive Officer of Dignitana AB. “The CHILL Registry is an incredible platform that will allow us to track progress and connect with physicians around the world to ensure that we can continue to deliver the most effective scalp cooling treatments available.” “Scalp cooling is well-recognized around the globe as a therapeutic solution to one of the most troublesome side effects of chemotherapy,” said CHILL Executive Board Member Dr. Corina van den Hurk, Netherlands Comprehensive Cancer Organisation.  “The launch of the CHILL Registry is a significant step forward as we work together to develop best practices in supportive care.” CHILL has designed an online registry that makes communication and global research accessible to all health care professionals interested in using scalp cooling with their chemotherapy patients. The registry collects data about severity of hair loss of patients with and without scalp cooling. For patients undergoing treatment with scalp cooling, physicians can also gather information on tolerance and satisfaction with the results of treatment. As scalp cooling results vary depending on several factors, the CHILL Registry amasses information including:   · Clinical: type and dose of chemotherapy, infusion time, post-infusion cooling time · Patient characteristics: age, ethnic background, hair thickness, chemical treatment of hair, smoking, body mass index · Efficacy: severity and pattern of hair loss, and in case of scalp cooling: tolerance and satisfaction · Follow up information: dependent on availability and willingness of patient to be contacted six months after treatment to evaluate hair growth and results to determine incidence of persistence hair loss Launching this unique initiative at the Multinational Association of Supportive Care in Cancer (MASCC) conference  June 22-24, 2017 in Washington, DC, the clinicians spearheading the CHILL registry and serving as the CHILL Executive Board include: · Corina van den Hurk, PhD  , Epidemiologist, Netherlands Comprehensive Cancer Organisation (IKNL) – Netherlands · Annie Young, PhD , Professor of Nursing, University of Warwick and University Hospital Coventry and Warwickshire NHS Trust – Coventry, United Kingdom · Frances Boyle, AM , MBBS (Hons 1), PhD Pharmacology, FRACP (Medical Oncology), Professor of Medical Oncology and Director of Patricia Richie Center for Cancer Care and Research, Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital and University of Sydney – Sydney, Australia  · Hope Rugo, MD , Professor of Medicine and Director, Breast Oncology and Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center – San Francisco, California, United States · Mario Lacouture, MD , Director, Oncodermatology Program, Memorial Sloan Kettering Cancer Center – New York, New York, United States · Julie Winstanley, PhD, MSc, CStat, CSci and Associate Professor, Patricia Ritchie Centre for Cancer Care and Research, Mater Hospital and University of Sydney – Sydney, Australia   “Hair loss associated with chemotherapy can be devastating for many women,” said oncologist Hope S. Rugo, MD, Professor of Medicine, Director, Breast Oncology and Clinical Trials Education at UC San Francisco and a breast cancer specialist with the UCSF Helen Diller Family Comprehensive Cancer Center. “Working with Dignitana to clinically test and introduce the first FDA-cleared scalp cooling medical device to the U.S. market, our aim has been to care for the emotional wellbeing of our patients as we aggressively treat their cancer. The clinician-led CHILL registry is a forward-looking commitment to providing patients with the best possible practice insights and innovations as scalp-cooling technology continues to advance and evolve.” Positive results from two separate multi-center clinical trials on scalp cooling were published in February 2017 by The Journal of the American Medical Association (JAMA). Both U. S. studies of breast cancer patients using the DigniCap  and Paxman  scalp cooling devices found that a majority of patients achieved favorable results from scalp cooling treatments to prevent hair loss. The scalp cooling medical device features a tight-fitting silicone cooling cap that is placed directly on the head, and an outer neoprene cap that insulates and secures the silicone cap. The cooling cap is connected to a cooling and control unit. A liquid coolant circulates throughout the silicone cap, delivering consistent and controlled cooling to all areas of the scalp. Once the cap is fitted to the head, the temperature of the scalp skin is significantly lowered, resulting in vasoconstriction with reduced delivery of chemotherapy to the scalp skin, as well as reduced cellular uptake of drugs due to decreased intra-follicular metabolic rate. These factors together minimize the hair loss that is a side effect of many chemotherapy agents.  THE CHILL Registry is funded by Dignitana , maker of The DigniCap® Scalp Cooling System and Paxman, maker of the Paxman Scalp Cooling System.

CEO to leave Dustin

The search process for his successor will be initiated immediately. Georgi Ganev will remain as CEO during his six-months notice period.   - Georgi Ganev has built a strong team and developed Dustin’s business through geographical expansion and a broadened offering during his five years as CEO. Thanks to a strong position and an efficient business model Dustin is well positioned for future growth. On behalf of the whole board I want to give my warmest thanks to Georgi for his great efforts for Dustin and wish him all the best in his future role, said Fredrik Cappelen, Chairman of the Board of Directors Dustin. - It has not been an easy decision to leave Dustin. I am very proud of what we have achieved together and is confident that the team at Dustin will continue to successfully develop the company, said Georgi Ganev CEO of Dustin. Georgi Ganev has been the CEO of Dustin since 2012. Contact person: Eva Ernfors, Head of Information eva.ernfors@dustin.se, +46 70 258 62 94 This information is information that Dustin Group AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on June 26, 2017. About Dustin Dustin is one of the leading Nordic resellers of IT products with associated services to companies, the public sector and private individuals. With its core business in e-commerce, Dustin functions as a bridge between the manufacturer’s wide-ranging offerings and customer requirements, in which Dustin’s employees support customers in finding the appropriate solution for them. Dustin is a one-stop-shop that offers some 200,000 products with associated services, features and solutions. Operations are conducted in Sweden, Denmark, Norway and Finland. The company has approximately 900 employees. Sales during the 2015/16 financial year amounted to approximately SEK 8.3 billion. About 90 per cent of Dustin’s income derives from the corporate market with a focus on small and medium-sized companies. Dustin Group has been listed on Nasdaq Stockholm since 2015 and has its head office in Nacka, Stockholm.

Carina Strand appointed Head of Group HR at Swedbank

Carina Strand is currently Head of HR at IBM Sweden, where she is also part of the Management Team. -Carina has a solid background within the HR area, and the right tools to support Swedbank's journey towards a modern and digital bank while increasing both employee satisfaction and pride. Carina's broad experience will be a very valuable asset in the Group Executive Committee and for all our 14,000 employees, says Birgitte Bonnesen, President and CEO of Swedbank. Carina Strand has held a couple of different HR positions within IBM during the last decade. -I really look forward to joining Swedbank. With its strong culture and values, and large customer base throughout Sweden and the Baltics, Swedbank has a unique position of capturing the opportunities of the digital transformation, which will create great benefits for both customers and employees, says Carina Strand, future Head of Group HR of Swedbank. Carina Strand will take on her new role on 1 October 2017. For further information:Josefine Uppling, Group Press Officer, Swedbank, +46 76 114 54 21 This announcement involves the disclosure of inside informationSwedbank AB (publ) is required to disclose this information pursuant to Regulation (EU) No 596/2014 on market abuse, the Swedish Securities Markets Act (2007:528), the Swedish Financial Instruments Trading Act (1991:980) and the regulatory framework of Nasdaq Stockholm. This information was sent to be published on 26 June 2017 at 8 am CET.

Cantargia: Preclinical studies of IL1RAP and CAN04 in solid tumours presented at EACR-AACR-SIC in Florence

Cantargia is developing the humanised antibody CAN04, against the target molecule Interleukin-1 Receptor Associated Protein (“IL1RAP”), for treatment of cancer. Cantargia has previously shown that antibodies targeted at IL1RAP can block IL-1 signalling and stimulate the killing of cancer cells in various preclinical cancer models. The data that was presented shows that IL1RAP is expressed in several cell lines from triple negative breast cancer and non-small cell lung cancer. CAN04 blocks the release of the tumorigenic molecules IL-6 and IL-8. CAN04 can also stimulate the immune system’s NK cells to kill these cell lines. The studies were conducted by Dr Ramin Massoumi’s team at Lund University and the results were presented as a poster by Dr Wondossen Sime. “Presentations of our CAN04 antibody at international scientific conferences are important for Cantargia”, CEO Göran Forsberg says. “This data highlights the potential of CAN04. In addition to our focus on non-small cell lung cancer and pancreatic cancer, triple negative breast cancer could be an important future disease in the context of CAN04 development”. For further information, please contact Göran Forsberg, CEOTelephone: +46 (0)46-275 62 60E-mail: goran.forsberg@cantargia.com This constitutes information that Cantargia is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 26 June 2017, at 8.30am. About Cantargia  Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing an antibody-based cancer treatment, which aims to attack cancer cells and arrest the inflammation of the tumour. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein “IL1RAP”, in cancer stem cells in patients with leukemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The Company has selected a product candidate, CAN04, for future studies in humans and development activities have been focused on non-small cell lung cancer and pancreatic cancer.  Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.

Itiviti delivers multi-protocol automated testing for CSE System

To deliver the solution, CSE deployed VeriFIX by Itiviti, the industry standard in automated testing, with multiple FIX protocol versions as well as proprietary binary protocols in order to implement full regression testing of order entry, market data feeds, and regulatory requirements for the CSE Trading System. This full regression testing suite facilitates validation of complete trading workflows across all protocols and interfaces. “Itiviti has enabled CSE to regression test our platform and receive automation quality benefits both of which has added operational efficiencies to our release cycles” said David Timpany, Vice President, Technology & Operations for CSE. “Our regression testing time frame has been reduced from multiple people for four weeks to an overnight automated test run with defect report generation. With next day feedback to our development team, we have dramatically decreased the defect turnaround timeframe. These improvements will help us to continue offering our clients a competitive advantage in the marketplace.” Multi-protocol technologies are a top priority at Itiviti. Itiviti’s solutions support both industry standard and proprietary protocols and are available for firms looking to redesign or scale-up their trading technology for future client demand. “We are pleased to continue to partner with CSE to accelerate deployment of CSE’s Trading System and help achieve cost and system efficiencies,” said Jesper Alfredsson, President Americas, Itiviti. “Our work with CSE is another example of how Itiviti can help achieve test automation for FIX and proprietary protocols.” Firms that invest in multi-protocol technologies will be the leaders in offering high quality, reliable market access for a broader range of market participants. About ItivitiItiviti is a world-leading technology provider for the capital markets industry. Trading firms, banks, brokers and institutional clients rely on Itiviti technology, solutions and expertise for streamlining daily operations, while gaining a sustainable competitive edge in global markets. With 13 offices and serving more than 400 customers worldwide, Itiviti was formed by uniting Orc Group, a leader in trading and electronic execution, and CameronTec Group, the global standard in financial messaging infrastructure and connectivity. From its foundation in 2016, Itiviti has a staff of 400 and an estimated annual revenue of SEK 700 million. Itiviti is committed to continuous innovation to deliver trading infrastructure built for today’s dynamic markets, offering highly adaptable platforms and solutions, enabling clients to stay ahead of competitive and regulatory challenges. Itiviti is owned by Nordic Capital Fund VII. About CSECSE, The Exchange for Entrepreneurs®, is home to more than 300 listed companies covering a broad range of industry sectors. CSE provides trade execution, smart routing, risk management, compliance and market information services for Canadian listed securities across multiple markets.   Recognized as an exchange by the Ontario Securities Commission in 2004, the CSE is designed to facilitate the capital formation process for public companies through a streamlined approach to company regulation that emphasizes disclosure and the provision of efficient secondary market trading services for investors.  For further information, please contact: Itiviti Jesper Alfredsson, President Americas, Itiviti, Tel: +1 312 541 4500, jesper.alfredsson@itiviti.comMegan Geldman, Senior Marketing Manager Americas, Itiviti, Tel: +1 312 541 4181, megan.geldman@itiviti.com www.itiviti.com Follow Itiviti on social media on Twitter @Itiviti_AB , on Facebook @ItivitiAB , and on LinkedIn   CSE David Timpany, Vice President, Technology & Operations, CSE, Tel: 416-367-7355, david.timpany@thecse.com  www.thecse.com; CSE blog at http://blog.thecse.com  Follow the CSE on social media on Twitter @CSE_News  and on Instagram and Facebook @CanadianSecuritiesExchange 

Ericsson demonstrates innovations at Mobile World Congress Shanghai

From June 28 to 30, Ericsson (NASDAQ: ERIC) will share successful customer case studies and demonstrate the latest innovations in 5G, IT and Cloud, and the IoT to customers, partners and media at Mobile World Congress Shanghai. Highlights on display at the Ericsson booth will include the latest 3.5GHz 5G radio, Big Data Analytics, and the IoT Accelerator  platform. Ericsson will participate in a full schedule of activities during the week of the event, under the theme “Making 5G real, partnership with Ericsson”, including: · June 27 – Ericsson will host a Unified Delivery Network conference with participants such as Asian operators and content providers. On the same day, Ericsson will make a joint announcement with China Telecom · June 28 – Ericsson, China Unicom and Qualcomm will make a joint announcement during a media conference at the Ericsson booth. Chris Houghton, Head of Market Area North East Asia at Ericsson, and Shao Guanglu, Executive Director and Senior Vice President of China Unicom, will address the media. Later that day, Ericsson Senior Vice President and Head of Business Area Digital Services Ulf Ewaldsson will make a keynote speech at the GTI Summit · June 29 – Ewaldsson will participate in a panel session at the Network Evolution Summit · June 30 – George Guo, Head of IT & Cloud, Market Area North East Asia, Ericsson will make a keynote speech at the Enterprise & The Cloud Summit Chris Houghton, Head of Market Area North East Asia at Ericsson, says: “At Mobile World Congress Shanghai, Ericsson will demonstrate how breakthroughs in 5G, IT and Cloud, and the IoT are revolutionizing industries. By redefining what’s possible with radio systems and federated network slicing, software-defined networking and network functions virtualization, and NarrowBand IoT, we’re pioneering a wide range of transformative solutions.” Ericsson at Mobile World Congress Shanghai 2017 Everything moves fast on the journey toward the Networked Society, and breakthroughs such as autonomous driving, remote surgery and immersive virtual reality are rapidly transforming industries of all kinds. Everywhere we look, companies are breaking out of their traditional comfort zones to adopt innovative and disruptive business models. Ericsson, the driving force behind 5G and the IoT, is a willing partner in the ongoing digital revolution. From June 28 to June 30, Ericsson is demonstrating cutting-edge technologies, innovative solutions and a wide range of customer success stories at Mobile World Congress Shanghai. Join us in Booth A61, Hall W4 at the Shanghai New International Exhibition Center (SNIEC) or engage with us online. See you there! NOTES TO EDITORS For media kits, backgrounders and high-resolution photos, please visit www.ericsson.com/press FOLLOW US: www.twitter.com/ericssonwww.facebook.com/ericssonwww.linkedin.com/company/ericsson www.youtube.com/ericsson MORE INFORMATION AT: News Center  media.relations@ericsson.com(+46 10 719 69 92) investor.relations@ericsson.com(+46 10 719 00 00) Ericsson is a world leader in communications technology and services with headquarters in Stockholm, Sweden. Our organization consists of more than 111,000 experts who provide customers in 180 countries with innovative solutions and services. Together we are building a more connected future where anyone and any industry is empowered to reach their full potential. Net sales in 2016 were SEK 222.6 billion (USD 24.5 billion). The Ericsson stock is listed on Nasdaq Stockholm and on NASDAQ in New York. Read more on www.ericsson.com.

Transcom appoints new CEO and becomes sister company with Xzakt following an acquisition by Altor

Stockholm, 26 June 2017 Michael Weinreich has been appointed new CEO of Transcom WorldWide (Transcom), replacing Johan Eriksson. Michael was previously CEO of Arvato Financial Services, but has recently also been a VC Partner at FinLeap. Michael will join Transcom on September 1. Michael has a comprehensive industry experience from hands-on call center operation management to sophisticated international business process outsourcing for collection and payment services. He is very much up-to-date in modern digital solutions due to his role as VC Partner and angel investor. “After several successful years as President & CEO of Transcom, Johan Eriksson recently informed the Board of his intention to leave his position. I would like to extend my gratitude for Johan Eriksson’s commitment and contribution in developing Transcom. I am also very grateful that Johan has promised to stay on to make the transition smooth. Michael has a great track-record from this industry and has exceptional international experience – which makes him perfect as the successor for the CEO role in Transcom” says Fredrik Cappelen, Chairman of Transcom. In parallel with the appointment of a new CEO, Transcom’s owner Altor Fund IV (Altor) has via a holding company acquired the Swedish customer care company Xzakt kundrelation (Xzakt) from the founder and owner Gunilla von Platen. Transcom and Xzakt will be structured as sister companies. The two brands will be run independently. Gunilla and Alfred von Platen will become minority owners in the holding company and partner with Altor in developing both Xzakt and Transcom. “I believe our new Group can build something exciting in this industry. Xzakt has created an unprecedented profitable growth-saga in the customer contact business. Now we will embrace the global footprint from Transcom and I believe we are just in the beginning of a wonderful journey together”, says Gunilla von Platen, founder of Xzakt. For further information, please contact: Stefan Pettersson, Head of Group Communications Telephone +46 70 776 80 88

AWAPATENT CHOOSES HiQ AS A PARTNER ON THE NEXT STAGE OF ITS DIGITAL JOURNEY

Collaboration will begin immediately and the focus will be on strategic projects that use a variety of smart digital solutions to improve and simplify work, both for Awapatent and the company’s clients. HiQ will also serve as Awapatent’s partner for a digital payment service for local and global clients that will come online at a future date. “Awapatent chose HiQ because of HiQ’s professionalism, creativity and expertise at the cutting edge of technology. We were looking for a supplier who can challenge us to think in new ways. HiQ has clearly demonstrated its ability to do just this throughout the entire process, through its creative approach, itsknow-how and its will to win – while also making every stage of the journey fun and thoroughly enjoyable,” says Marie-Louise Lindblom, Head of Aftermarket Services at Awapatent. “We won this assignment in the face of stiff competition, so we are incredibly proud and pleased that Awapatent has chosen to work with HiQ. Our collaboration with Awapatent extends all the way from idea, through design and development, to implementation and ongoing optimisation,” says Peter Sognefur, Sales Manager with HiQ Skåne. Awapatent, a leading consultancy organisation in intellectual property with 16 offices in Sweden, Denmark, Germany and China/Hong Kong, is working at a time that is characterised by a number of dramatic changes. Innovations in genetics, nanotechnology and software development, together with amendments to existing laws and the forward march of globalisation are posing new challenges and creating new demands for Awapatent and its clients. “Being part of this process of development together with Awapatent fits in well with HiQ’s aim and ambition to simplify business models and processes through digital strategies and development,” says Anna Kleine, Managing Director, HiQ Skåne. Awapatent is a leading consultancy organisation in intellectual property (patents, design and trademark protection, copyright, etc.) The company was founded in Malmö, Sweden, 120 years ago by the Swedish engineer Anders Wilhelm Anderson (whose initials form part the company name). Today Awapatent has 300 employees. For further information, please contact:  Anna Kleine, CEO, HiQ Skånetel: +46 70-359 93 31, e-mail: anna.kleine@hiq.seErik Ridman, Head of Communications, HiQ,tel: +46 70 750 8060, e-mail: erik.ridman@hiq.se

Novacura signs new deal with Norwegian civil Protection agency

DSB is responsible for developing Norway’s ability to prevent and manage accidents and crises. The agency employs 240 people in 20 different district offices across Norway and their headquarters in Tønsberg, and engage an additional 8000 staff members who is called in case of an emergency. – With IFS Applications and Novacura Flow, the Civil Defence can in addition to managing all information also communicate directly with all employees and handle all reporting and documentation. The system also supports mobile processes. The recruitment of extra staff is one area that the Civil Defence needs help documenting. Another area is to improve logistics management to simplify keeping and updating inventory. – They are also in the process of improving their incident reporting. In case of emergency, it may be crucial to be abler to keep track of both people, equipment and resources in a single well-integrated system. The Norwegian Civil Defence has previously used several different systems for different processes that failed to communicate effectively with each other. – We are proud to be a part of DSB’s important work and look forward to work together to improve and streamline their information management, says Aksel Jarlbäck. The system is scheduled to be operational in October of 2018. Read more about the Norwegian Civil DefenceThe Norwegian Civil Defence has competencies, and is organized and equipped to render operative support to the emergency and rescue departments. The department provides training in the areas of response and rescue for own personnel and other parties within the Norwegian rescue services, and support to international humanitarian rescue operations and operate countrywide public warning service in the event of immediate danger. In addition, the civil Defence provides support to international humanitarian rescue operations. http://www.sivilforsvaret.no/s/English/ Press contactUlrica Björnsdotter+46 73-8501127ulrica.bjornsdotter@novacura.se

Nurminen Logistics Aims to Grow Its Business in Accordance with Its Strategy and Announces Capital Arrangement

Nurminen Logistics Plc                Stock Exchange Release              26 June 2017 at 1:50 P.M Finnish time The Board of Directors of Nurminen Logistics Plc (”Nurminen Logistics” or the “Company”) has resolved to enhance the strategic targets of the Company. In accordance with the current strategy of the Company, the Company focuses on growing and developing its business and to lengthen the logistic value chain both organically and through potential acquisitions while the focus areas are to develop rail services, industrial logistics services and harbour operations. The Board of Directors of the Company has resolved to strengthen the Company’s capabilities to carry out the initiatives promoting the Company’s strategy through capital arrangements that will strengthen the capital structure of the Company. Based on the authorization granted by the Annual General Meeting of Shareholders on 21 April 2017, the Board of Directors of Nurminen Logistics has resolved on the rights offering based on the pre-emptive subscription rights of the current shareholders, whereby a maximum of 29,229,764 new shares are offered for subscription to the shareholders at a subscription price of EUR 0.28 (the “Rights Offering”). The Rights Offering will not include a right to secondary subscription, and as to the shares that have not been subscribed for, the Board of Directors of the Company may decide on the offering and allocation of shares to certain parties. Certain parties have, in accordance with certain customary terms and conditions, given undertakings to subscribe for new shares that have not been subscribed for pursuant to the subscription rights of the current shareholders (“Private Placement”). Additionally, in accordance with certain terms and conditions, Ilmarinen Mutual Pension Insurance Company (”Ilmarinen”) has undertaken to subscribe for new shares and paying the subscription price by setting off the Company’s payment obligations to Ilmarinen pertaining to repurchase of certain real estate properties from Ilmarinen (the ”Sale and Lease Back Arrangement”) (the “Directed Conversion Offering”). With regard to the Private Placement, the maximum number of subscriptions in the subscription undertakings the Company has received represent approximately 59.87 per cent of the New Shares offered in the Rights Offering and, with regard to the Directed Conversion Offering, represents approximately 30.04 per cent of the new shares offered in the Rights Offering. In addition to the aforesaid, certain members of the Board of Directors and the management of the Company have informed that they will exercise their subscription rights or they have undertaken to subscribe for New Shares. In addition to the Rights Offering, the Company and Ilmarinen have agreed on the arrangement, whereby EUR 1.5 million of the Company’s payment obligations to Ilmarinen pertaining to the Sale and Lease Back Arrangement will be used as consideration to subscribe for a convertible equity hybrid bond (the “Convertible Hybrid Bond”), which Ilmarinen has undertaken to fully subscribe for. The Convertible Hybrid Bond is subject to the resolution of the Extraordinary General Meeting of Shareholders of the Company authorizing the Board of Directors of the Company to resolve on a share issue and/or the issue of special rights entitling to the shares for a maximum amount of 5,330,000 new shares, in addition to, without changing the current authorization granted by the Annual General Meeting of Shareholders of the Company to the Board of Directors on 21 April 2017. The Rights Offering, the Private Placement and the Directed Conversion Offering are subject to the execution of the Convertible Hybrid Bond. In the event that (i) the Extraordinary General Meeting of Shareholders of the Company will not authorize the Board of Directors of the Company to resolve on a share issue and/or the issue of special rights entitling to shares or (ii) the Convertible Hybrid Bond will not be fully subscribed for, the Board of Directors of the Company will cancel the Rights Offering and the Subscription Price paid for the New Shares will be refunded to those who have subscribed for shares. In the event that the Board of Directors resolves to cancel the Rights Offering as described above, any unexercised Subscription Rights expire without any compensation and investors, who have not subscribed for New Shares based on the Subscription Rights lose money paid for the Subscription Rights. The Rights Offering The Rights Offering in Brief · Gross proceeds of approximately EUR 5.7 million to promote the strategic initiatives in accordance with the strategy of the Company, to strengthen the balance sheet of the Company and to relieve the debt structure of the Company. Additionally, Ilmarinen has undertaken to subscribe for New Shares that have not been subscribed for, for a maximum sum of EUR 2,458,400.00, whereby the subscription price is paid by setting off the Company’s payment obligations to Ilmarinen pertaining to the Sale and Lease Back Arrangement, which will decrease the amount of debt owed by the Company but the Company will not retain any proceeds from the Directed Conversion Offering. · Two (2) new shares for each one (1) existing share owned on the record date 28 June 2017. · The subscription price is EUR 0.28 per new share · The Nurminen Logistics shares will trade ex-rights from 27 June 2017. · The subscription period commences on or about 3 July 2017 at 9.30 Finnish time and ends on or about 21 July 2017 at 16.30 Finnish time. · Trading in Subscription Rights commences on or about 3 July 2017 and ends on or about 17 July 2017. The Rights Offering in General  On 26 June 2017, the Board of Directors of the Company has, based on the authorization granted by the Annual General Meeting of Shareholders of the Company, resolved on the Rights Offering, whereby the Company will issue a maximum of 29,229,764 new shares (the “New Shares”). The Company will give all of its current shareholders who are registered in Nurminen Logistics’ shareholders’ register maintained by Euroclear Finland Ltd on the record date 28 June 2017 (the “Record Date”), two (2) freely transferable subscription rights in the form of a book-entry (the “Subscription Right”) for each share owned on the Record Date. Each one (1) Subscription Right will entitle its holder to subscribe for one (1) New Share for the subscription price of EUR 0.28 (the “Subscription Price”). The Subscription Price corresponds to an implied discount to the theoretical ex-rights price of approximately 71.6 per cent, based on the closing share price of EUR 0.985 on 22 June 2017. The shares will trade ex-rights from 27 June 2017. The subscription period will commence on or about 3 July 2017 and end on or about 21 July 2017. The Subscription Rights will be subject to public trading on or about 3 July 2017 to on or about 17 July 2017. As a result of the Rights Offering, the total number of shares in the Company may increase from 14,674,410 existing shares and, together with the New Shares, to a maximum of 43,904,174 Shares. Assuming that the Rights Offering will be fully subscribed for, the New Shares represent 199.19 per cent of the Company’s existing shares and related voting rights prior the Rights Offering and 66.58 per cent of all of the Company’s shares and related voting rights after the completion of the Rights Offering. The Rights Offering will not include the right to secondary subscription. Subscription Undertakings The largest shareholder of the Company, Juha Nurminen and JN Uljas Oy, a company controlled by Mr. Nurminen, as well as Jukka Nurminen, Mikko Nurminen and Satu Lassila, representing in aggregate approximately 76.13 per cent of the existing shares and related voting rights in the Company on the date of this release, have notified the Company that they will not be exercising, selling or otherwise transferring the their Subscription Rights in the planned Rights Offering. In the event that not all of the New Shares have been subscribed for pursuant to the Subscription Rights, the Board of Directors of the Company may resolve on the offering and allocation of the New Shares, which have not been subscribed for, for the Subscription price in private placement. Suomen Kauppayhtiöt Oy, K. Hartwall Invest Oy Ab, Avant Tecno Oy, Eva Hisinger-Jägerskiöld, Apteekkien Eläkekassa and Matti Eestilä have each, in accordance with certain customary terms and conditions, undertaken to subscribe for New Shares at the Subscription Price, in so far as they have otherwise not been subscribed for and paid for pursuant to the Subscription rights, however, only to the extent that each of their holding in the Company remains under 30 per cent and in aggregate for a maximum sum of as follows: Suomen Kauppayhtiöt Oy for maximum sum of EUR 1,600,000.00, K. Hartwall Invest Oy Ab for a maximum sum of EUR 1,000,000.00, Avant Tecno Oy for a maximum sum of EUR 1,000,000.00, Eva Hisinger-Jägerskiöld for maximum sum of EUR 500,000.00, Apteekkien Eläkekassa for a maximum sum of EUR 500,000.00 and Matti Eestilä for maximum sum of EUR 300,000.00 (”Private Placement”). Additionally, in accordance with certain terms and conditions, Ilmarinen has undertaken to subscribe for New Shares at the Subscription Price by setting off the Company’s payment obligations to Ilmarinen pertaining to the Sale and Lease Back Arrangement for a maximum sum of EUR 2,458,400.00. (the “Directed Conversion Offering”), in so far as New Shares have not been subscribed for pursuant to the Subscription Rights, provided that Ilmarinen’s holding in the Company remains under 20 per cent. In the Directed Conversion Offering, the subscription is paid for in full by using the payment obligations of the Company to Ilmarinen pertaining to the Sale and Lease Back Arrangement as consideration for the subscription of shares. The Directed Conversion Offering will decrease the amount of debt owed by the Company but the Company will not retain any proceeds from the Directed Conversion Offering.     The Company will publish the initial result of the Rights Offering on or about 24 July 2017 and the final result on or about 28 July 2017. Terms and conditions of the Rights Offering are attached as Appendix to this stock exchange release. Use of Proceeds The gross proceeds to Nurminen Logistics from the Rights Offering and from the Private Placement executed potentially after the Rights Offering, will be approximately EUR 5.7 million. Additionally, Ilmarinen has undertaken to subscribe for New Shares that have not been subscribed for, for a maximum sum of EUR 2,458,400.00, whereby the subscription price is paid by setting off the Company’s payment obligations to Ilmarinen pertaining to the Sale and Lease Back Arrangement that decreases the amount of debt owed by the Company but the Company will not retain any proceeds from the Directed Conversion Offering.   The purpose of the Rights Offering is to promote the strategic initiatives in accordance with the strategy of the Company, to strengthen the balance sheet of the Company and to relieve the debt structure of the Company. Publication of the Prospectus Nurminen Logistics has filed a prospectus related to the Rights Offering for approval with the Finnish Financial Supervisory Authority, which will be published on or about 26 June 2017. The prospectus will be available on Nurminen Logistics’s website at www.nurminenlogistics.fi on or about 26 June 2017. Convertible Equity Hybrid Bond between Nurminen Logistics and Ilmarinen In order to enhance the strategic targets of Nurminen Logistics, to strengthen the balance sheet of the Company and to relieve the debt structure of the Company, the Company and Ilmarinen have agreed on the convertible equity hybrid bond (equity convertible bond) (the “Convertible Hybrid Bond”) of EUR 1,500,000.00, which will be offered to Ilmarinen in derogation from the pre-emptive rights of the shareholders to be fully subscribed for. The Convertible Hybrid Bond will be fully subscribed for by using the Company’s payment obligations to Ilmarinen pertaining to the Sale and Lease Back Arrangement as consideration for the subscription of the Convertible Hybrid Bond. The Convertible Hybrid Bond is subject to the resolution of the Extraordinary General Meeting of Shareholders of the Company authorizing the Board of Directors of the Company to resolve on a share issue and/or the issue of special rights entitling to the shares for a maximum amount of 5,330,000 new shares, in addition to, without changing, the current authorization granted by the Annual General Meeting of Shareholders of the Company to the Board of Directors on 21 April 2017. If the Extraordinary General Meeting grants the Board the aforesaid authorization, the Company will make a separate announcement on the issuance and subscription of the Convertible Hybrid Bond. Extraordinary General Meeting of Shareholders The Board of Directors of the Company has resolved in relation to the Convertible Hybrid Bond to call for an Extraordinary General Meeting of shareholders of the Company to be held on 17 July 2017. The Company will issue a notice of the General Meeting on a separate release. Nurminen Logistics PlcThe Board of Directors Further information: Olli Pohjanvirta, Chairman of the Board of Directors, telephone +358 40 900 6977Marko Tuunainen, President and CEO, telephone +358 10 545 7011 Distribution: Nasdaq Helsinki OyMajor mediawwww.nurminenlogistics.com IMPORTANT INFORMATION: The information contained herein is not for publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, South Africa or any other country where such publication or distribution would violate applicable regulation or would require any measure to be undertaken, in addition to the requirements under Finnish law. The issue, exercise or sales of securities in the offering are subject to specific legal or regulatory restrictions in certain jurisdictions. The Company assumes no responsibility in the event there is a violation by any person of such restrictions. The information contained herein shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. Investors must neither accept any offer for, nor acquire, any securities to which this document refers, unless they do so on the basis of the information contained in the applicable prospectus published by the Company. This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia). This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, unless registered under the Securities Act or pursuant to an exemption from the registration requirements of the Securities Act and in compliance with any applicable state securities laws of the United States. There is no intention to offer securities in the United States. The Company has not authorized any offer to the public of securities in any Member State of the European Economic Area other than Finland. With respect to each Member State of the European Economic Area other than Finland and which has implemented the Prospectus Directive (each, a “Relevant Member State”), no action has been undertaken or will be undertaken to make an offer to the public of securities requiring publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in Relevant Member States (a) to any legal entity which is a qualified investor as defined in the Prospectus Directive; or (b) in any other circumstances falling within Article 3(2) of the Prospectus Directive. For the purposes of this paragraph, the expression an “offer of securities to the public” means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to exercise, purchase or subscribe the securities, as the same may be varied by any measure implementing the Prospectus Directive in that Relevant Member State and the expression “Prospectus Directive” means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression “2010 PD Amending Directive” means Directive 2010/73/EU. This announcement does not constitute an offer of securities to the public in the United Kingdom. No prospectus has been or will be approved in the United Kingdom in respect of the securities. This announcement and the offer when made are only addressed to and directed at persons who (1) are outside the United Kingdom, (2) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000, Order 2005 as amended (the “Order”) or are persons falling within Article 49(2)(a) to (d) of the Order (“high net worth companies, unincorporated associations, etc.”) or (3) to persons to whom an invitation or inducement within the meaning of section 21 of the Financial Services and Markets Act 2000 may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). The information set out in this announcement must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons. Appendix                                        Terms and Conditions of the Rights Offering

Nurminen Logistics Plc will publish prospectus regarding the Rights Offering, Capitalization and indebtedness and working capital statement

Nurminen Logistics Plc                                             Stock Exchange Release              26 June 2017 at 1:55 P.M. Finnish TimeThe Finnish Financial Supervisory Authority has today approved the Finnish language version of the prospectus regarding to the rights offering of maximum of 29 229 764 new shares of Nurminen Logistics ("Nurminen Logistics"). The Finnish listing prospectus will be available on Nurminen Logistic’s Finnish website at www.nurminenlogistics.fi as of 26 June 2017. The terms and conditions of the Rights Offering were published in a separate stock exchange release on 26 June 2017. The following table sets out the Company’s capitalisation and indebtedness as at 30 April 2017. The figures are unaudited and they are based on the Company’s group-internal monthly reports regarding the Company’s capitalisation and indebtedness as at 30 April 2017. The table is to be read in conjunction with the audited consolidated financial statements for the financial years ending 31 December 2016 and 31 December 2015 included in Appendix A of the Prospectus. No significant changes have taken place in the Company’s capitalisation and indebtedness since 30 April 2017. 30 April 2017MEUR  (unaudited) Current interest-bearing debt Secured  2 Total  2  Non-current interest-bearingdebt Secured   22 Total  22  Total interest-bearing debt  24  Shareholders’ equity belonging tothe owners of the parent company Share capital  4 Hedge reserve Contingency reserve Hybrid bond Other reserves  21 Translation differences  -7 Retained earnings   -13 Total shareholders’ equity  6  Total shareholders’ equity and 30 interest-bearing debt  Net indebtedness MEUR Liquidity (A) Cash and cash equivalents  4 Total  4  Current interest-bearing debt(B) Financial debt  2 Total  2  Net current indebtedness (C = -2 B–A)  Non-current interest-bearing debt(D) Financial debt   22 Total  22  Net indebtedness (C+D)  21  Working Capital Statement The Company’s current working capital is not, as at the date of this Prospectus, sufficient to cover its needs in the next 12 months. If the Company’s cash flow develops in the manner predicted and planned by the Company, the working capital will, as at the date of the Prospectus, be sufficient for the Company’s operative needs for the next 12 months, but the cash flow will not, according to the Company’s management, be sufficient to pay the obligations subject to security limits related to the customs bonds received by the Company from the financial institutions. The securities related to the customs bonds are, in the opinion of the Company’s management, customary in the forwarding business. The Company has customs securities related to the customs bonds from financial institutions, and the covenant terms included therein impose conditions, for instance, regarding the Company’s equity ratio (the total amount of the security limits received from the financial institutions stands approximately at EUR 8.9 million, of which amount, a share of approximately EUR 7.5 million is subject to covenant terms) (see section “Information about Nurminen Logistics—Significant Agreements—Financing Agreements”). The covenant terms had been breached on 31 December 2016, but the Company has received an undertaking from the financiers until 31 December 2017 pursuant to which no sanctions will be imposed on the Company as a result of a breach of the covenant terms. In the opinion of the Company’s management, the covenant terms of the financing agreement would not be met by 31 December 2017, upon the occurrence of which, the obligations subject to the customs security would immediately fall due for payment. It is also not certain whether the Company is able to operate in the future in such a way that the covenant and other terms included in its financing agreements would not be breached and whether the Company’s financiers would be willing, in connection with possible breaches, to re-negotiate the terms of financing or security without requiring the expedited or immediate payment of the loans or release of the security. Provided that the Rights Offering is subscribed in full and the Convertible Hybrid Bond is executed, the Company will, according to its management, be in a position to meet the financiers’ covenant terms related to the customs securities. (See section “Background and Reasons for the Rights Offering and the Use of Proceeds”.) According to the Company’s management, the Directed Conversion Issue and the Convertible Hybrid Bond, in respect of which the Company has received subscription undertakings from Ilmarinen in the manner provided for in certain terms and conditions and the subscription of which will reduce the amount of the Company’s debt (by approximately EUR 2.4 million in the case of the Directed Conversion Issue and by approximately EUR 1.5 million in the case of the Convertible Hybrid Bond), make it possible for the Company to meet the covenant terms of the security limits granted by the financing banks. Provided that the Company meets the financing banks’ covenant terms in the manner described above, the customs security agreed upon by the Company with the financing banks would be in force until 30 June 2018. The Company and the financing banks have negotiated, at regular intervals, on the customs securities, and it is the Company’s intention to have an agreement on the customs securities with the financing banks even after 30 June 2018. Should the Company not be successful in agreeing with the financing banks on the customs securities after 30 June 2018, the Company shall take steps to have the resulting need for additional financing covered. According to the Company’s management, the steps required to cover the need for additional financing could include (i) the reorganisation of the financing and securities, (ii) the sale of the Company’s operations and assets, and (iii) combinations of the above-mentioned means. Should the Rights Issue and the Convertible Hybrid Bond not be executed and should the Company’s assets not be sufficient for the payment of the customs security obligations in a situation in which the covenant terms of the security limits had not been met, the need for financing shall be covered by means of additional financing and by resorting to other measures. The Company’s management has assessed the measures required to be taken in the case of possible additional financing, including (i) the reorganisation of the financing and securities, (ii) the sale of the Company’s operations and assets, and (iii) combinations of the above-mentioned means. Nurminen Logistics PlcBoard of Directors Additional information: Olli Pohjanvirta, Chairman of the Board of Directors, telephone +358 40 900 6977Marko Tuunainen, President and CEO, telephone +358 10 545 7011 Distribution: Nasdaq Helsinki OyKeskeiset tiedotusvälineetwwww.nurminenlogistics.fi IMPORTANT INFORMATION The information contained herein is not for publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, South Africa or any other country where such publication or distribution would violate applicable regulation or would require any measure to be undertaken, in addition to the requirements under Finnish law. The issue, exercise or sales of securities in the offering are subject to specific legal or regulatory restrictions in certain jurisdictions. The Company assumes no responsibility in the event there is a violation by any person of such restrictions. The information contained herein shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. Investors must neither accept any offer for, nor acquire, any securities to which this document refers, unless they do so on the basis of the information contained in the applicable prospectus published by the Company. This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States and the District of Columbia). This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, unless registered under the Securities Act or pursuant to an exemption from the registration requirements of the Securities Act and in compliance with any applicable state securities laws of the United States. There is no intention to offer securities in the United States. The Company has not authorized any offer to the public of securities in any Member State of the European Economic Area other than Finland. With respect to each Member State of the European Economic Area other than Finland and which has implemented the Prospectus Directive (each, a “Relevant Member State”), no action has been undertaken or will be undertaken to make an offer to the public of securities requiring publication of a prospectus in any Relevant Member State. As a result, the securities may only be offered in Relevant Member States (a) to any legal entity which is a qualified investor as defined in the Prospectus Directive; or (b) in any other circumstances falling within Article 3(2) of the Prospectus Directive. For the purposes of this paragraph, the expression an “offer of securities to the public” means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to exercise, purchase or subscribe the securities, as the same may be varied by any measure implementing the Prospectus Directive in that Relevant Member State and the expression “Prospectus Directive” means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State and the expression “2010 PD Amending Directive” means Directive 2010/73/EU. This announcement does not constitute an offer of securities to the public in the United Kingdom. No prospectus has been or will be approved in the United Kingdom in respect of the securities. This announcement and the offer when made are only addressed to and directed at persons who (1) are outside the United Kingdom, (2) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000, Order 2005 as amended (the “Order”) or are persons falling within Article 49(2)(a) to (d) of the Order (“high net worth companies, unincorporated associations, etc”) or (3) to persons to whom an invitation or inducement within the meaning of section 21 of the Financial Services and Markets Act 2000 may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons”). The information set out in this announcement must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.

NOTICE TO THE EXTRAORDINARY GENERAL MEETING

Nurminen Logistics Plc          Stock Exchange Release       26 June 2017 at 2 p.m. Finnish time                              The Board of Directors of Nurminen Logistics Plc is calling to convene an Extraordinary General Meeting of shareholders to be held on Monday 17 July 2017 starting at 3:00 p.m. Finnish time at the address Satamakaari 24, 00980 Helsinki. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 2:30 p.m. Finnish time. At the Extraordinary General Meeting, the following matters will be considered: 1. Opening of the meeting2. Calling the meeting to order3. Election of persons to confirm the minutes and to supervise the counting of votes4. Recording the legality of the meeting5. Recording the attendance at the meeting and adoption of the list of votes6. Authorizing the Board of Directors to resolve on share issues as well as the issuance of options and other special rights entitling to shares The Board of Directors proposes to the Extraordinary General Meeting that the General Meeting authorizes the Board of Directors to resolve on share issues and/or the issuance of special rights entitling to shares pursuant to Chapter 10 Section 1 of the Finnish Companies Act. Based on the aforementioned authorization the Board of Directors may issue or assign, either by one or several resolutions, shares and/or special rights an amount which corresponds to a maximum of 5,330,000 new shares so that the aforementioned shares and/or special rights could be used, inter alia, for the financing of company and business acquisitions or other business transactions and investments, the expansion of the ownership structure, financing arrangement, remuneration of the members of the Board of Directors and/or for the creation of incentive schemes and for engaging personnel. The authorization would entitle the Board of Directors to resolve on share issues and the issuance of options and other special rights entitling to shares in in every way to the same extent as could be resolved by the General Meeting, including the Board of Director’s right to resolve on directed share issues and/or the issuance of special rights entitling to shares. The authorization would entitle the Board to resolve on a share issue with or without payment. The authorization for deciding on a share issue without payment would also include the right to resolve on a share issue to the company itself, so that the authorization may be used in such a way that in total no more than one tenth (1/10) of all shares in the company may from time to time be in the possession of the company and its subsidiaries. It is proposed that the authorization will be valid until 17 July 2022 and that it will not revoke the authorization granted to the Board of Directors by the Annual General Meeting on 21 April 2017, which will be valid until 30 April 2018 and which authorizes the issue of a maximum 30,000,000 company shares. 7. Closing of the meeting DOCUMENTS OF THE GENERAL MEETING The aforementioned resolution proposal of the Board of Directors on the agenda of the General Meeting as well as this notice are available on the website of Nurminen Logistics Plc at www.nurminenlogistics.com. Nurminen Logistics’ financial statement, annual report and the auditor’s report and other documents required by the Finnish Companies Act are available on the aforementioned website. The resolution proposal of the Board of Directors, financial statements and other documents required by the Finnish Companies Act are also available at the General Meeting and copies of them as well as of this notice will be sent to shareholders upon request. The minutes of the General Meeting will be available on the aforementioned website 31 July 2017 at the latest. INSTRUCTIONS FOR THE PARTICIPANTS IN THE MEETING The Right to Participate and Registration Each shareholder who is registered on 5 July 2017 in the shareholders’ register of the company held by Euroclear Finland Ltd has the right to participate in the General Meeting. A shareholder whose shares are registered on their personal Finnish book-entry account is registered in the shareholders’ register of the company. A shareholder who wants to participate in the General Meeting shall register for the meeting no later than 12 July 2017 at 10.00 a.m. Finnish time by giving a prior notice of participation. Such notice can be given a) by email: yhtiokokous@nurminenlogistics.com; b) by telephone to: 010 545 8820 (Monday­Friday 9:00­16:00 Finnish time); c) by letter to: Nurminen Logistics Plc, Extraordinary General Meeting, Satamakaari 24, 00980 Helsinki In connection with the registration, a shareholder shall notify their name, personal identification number, address, telephone number as well as the name and personal identification number of a possible assistant or proxy representative. The personal data given to Nurminen Logistics by the shareholders is used only in connection with the General Meeting and with the processing of necessary related registrations. Proxy representatives and powers of attorney A shareholder may participate in the General Meeting and exercise their rights at the meeting by a way of proxy representation. A proxy representative of a shareholder shall produce a dated proxy document or otherwise in a reliable manner demonstrate their right to represent the shareholder. If a shareholder participates in the General Meeting by means of several proxy representatives representing the shareholder with shares in different book-entry accounts, the shares by which each proxy representative represents the shareholder shall be identified in connection with the registration for the meeting. Possible original versions of the proxy documents are requested to be delivered in to Nurminen Logistics Plc, General Meeting, Satamakaari 24, 00980 Helsinki, before the end of the registration period. Holder of nominee registered shares A holder of nominee registered shares has the right to participate in the Extraordinary General Meeting by virtue of such shares, based on which he/she on the record date of the Extraordinary General Meeting on 5 July 2017, would be entitled to be registered in the shareholders’ register of the company held by Euroclear Finland Ltd. The right to participate in the Extraordinary General Meeting requires, in addition, that the shareholder on the basis of such shares has been temporarily registered into the shareholders’ register held by Euroclear Finland Ltd at the latest by 12 July 2017, 10:00 a.m. EET. As regards nominee registered shares this constitutes due registration for the Extraordinary General Meeting. A holder of nominee registered shares is advised to request without delay necessary instructions regarding the temporary registration in the shareholders’ register of the company, the issuing of proxy documents and preregistration for the Extraordinary General Meeting from his/her custodian bank. The account manager of the custodian bank has to register a holder of nominee registered shares, who wishes to participate in the Extraordinary General Meeting, temporarily in the shareholders’ register of the company by the time stated above at the latest. Other instructions and information Pursuant to Chapter 5, Section 25 of the Finnish Companies Act, a shareholder who is present at the Extraordinary General Meeting has the right to request information with respect to the matters considered at the meeting. On the date of this notice, 26 June 2017, the total number of shares and voting rights in Nurminen Logistics Plc is 14,674,410. In Helsinki, 26 June 2017 NURMINEN LOGISTICS PLC The Board of Directors DISTRIBUTION                                                                   Nasdaq HelsinkiMajor mediawww.nurminenlogistics.com Nurminen Logistics is a listed company established in 1886 that offers logistics services. The company provides high-quality forwarding, cargo handling and value added services as well as railway transports and related to it project transport services to its customers. The main market areas of Nurminen Logistics are Finland, Russia and its neighbouring countries. 

Swedish digital forensics company Bitsec AB joins forces with Nixu to form even stronger European cybersecurity services company

Nixu CorporationPress release on 26.6.2017 at 14:15 EET      Swedish digital forensics company Bitsec AB joins forces with Nixu to form even stronger European cybersecurity services companyNixu has now one of the largest cybersecurity services teams in the fragmented Swedish market Nixu, a focused cybersecurity company, has local operations in Sweden since 2016 when Europoint Networking AB and Safeside Solutions AB joined the company. Nixu’s start in Sweden has been successful and now Nixu continues to expand its operations by acquiring Bitsec AB specialized in digital forensics, penetration testing and IT security services. Nixu’s growth vision is to become a go-to-partner in cybersecurity services for companies headquartered in Northern Europe and the best place to work for cybersecurity professionals. Following its strategy, Nixu has rapidly grown to be over 300 person strong with offices in Finland, Sweden, Netherlands, USA and Romania. In Sweden the team of over 60 cybersecurity specialists can now better deliver Nixu’s holistic cybersecurity services portfolio. Bitsec’s strong technical expertise especially in data breach investigation, where Bitsec founder André Catry is a well-known expert, complements the existing competences of the Swedish team and enables a wider offering. Nixu is now able to offer the Nixu Cyber Defense Center –detection and response service to Sweden with local, Swedish speaking Tier 3 -incident responders on-call. “After establishing Nixu in the Swedish market, we have received a lot of feedback from large enterprise clients who have wishes for a more comprehensive cybersecurity services offering from one partner. Now we are in a unique position to help Swedish clients to implement their new digital services securely and ensure their availability despite the cyber threats. I’m delighted to welcome Bitsec experts to join the Nixu family. I truly believe that the experts of both companies will learn a lot from each other. With this great team in Sweden, we aim to continue our growth and look for new teams and talented individuals to join the family“, says Petri Kairinen, Nixu CEO."The joint company is a great example of merging people and competencies generating further increase of client value. While getting to know the Nixu team it is obvious our organizations carry the same type of cultural background and motivation based upon the passion for cybersecurity and technology. This has me convinced employees from both organizations will significantly benefit from this matchup. We are also now able to offer new services, such as 24/7 detection of incidents, to our clients from Nixu’s existing portfolio. Based on the uptake in client demand, the value to our personnel and increase in services we will be able to jointly offer; I am convinced the new setup is of significant benefit to all involved", says Jesper Svegby, CEO of Bitsec AB.NIXU CorporationFurther information:CEO Petri Kairinen, Nixu CorporationTelephone +358 40 832 1832, e-mail: petri.kairinen@nixu.com CEO Jesper Svegby, Bitsec ABTelephone +46 733 56 54 56, e-mail: jesper.svegby@bitsec.se Distribution:main mediawww.nixu.com/enNixu in brief:Nixu Corporation is a cybersecurity company. We work to improve our clients’ cybersecurity in solution areas of Corporate IT, Digital Business and Industrial Internet. Our clients trust Nixu in projects where developing, implementing or assessing of information security is a must. We ensure the confidentiality of our clients' data, business continuity and ease-of-access to digital services through planning and mitigation of cybersecurity risks.www.nixu.com, www.nixu.com/en/blog and twitter: @nixutigerteamBitsec in brief:Bitsec is a privately owned Swedish company which started in 2006 with offices in Stockholm and Karlstad, and operates in the area of IT & Information security. Our strength lies with our highly competent consultants whom we dare to call some of the best in the world, proven by our track record not only with highly satisfied customers but with numerous final positions in the annual Code Gate competition.We offer a variety of services such as: deep technology analysis of systems and code, incident response, forensics, penetration and 360perimeter analysis.  Since its inception, Bitsec has been working widely throughout the IT security area locally, as well as on the international scene supporting our clients wherever and whenever needed. Our customers ranges from authorities, major international groups as well as medium-sized private companies. Throughout our history we have proven our point: We know what´s going on!www.bitsec.se MyNewsdesk: https://www.mynewsdesk.com/se/bitsec LinkedIn: https://www.linkedin.com/company/bitsec-ab and twitter: @BITSECCYBER

Aspire Global plc publishes prospectus in connection with its listing on Nasdaq First North Premier in Stockholm

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, ISRAEL OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE For the complete press release follow this link: https://www.aspireglobal.com/ipo For additional information, contact:Tsachi Maimon, CEOTel. +356 79 777 898e-mail: tsachi@aspireglobal.com Carl Klingberg, ChairmanTel. +46 708 898 989e-mail: carl.klingberg@aspireglobal.com About Aspire Global Aspire Global is a Business to Business (“B2B”) service provider for the online gaming market and offers its B2B partners a full-service solution for launching and operating online casinos. In addition, Aspire Global holds several local gaming licenses enabling its partners to fulfill their full potential. With more than ten years of operational experience in managing casino networks and developing in-house proprietary technology, Aspire Global offers an online gaming solution which ensures that every aspect of partners’ casinos, from regulation and compliance to payment processing, risk management, CRM, support and player value optimisation, runs as efficiently and effectively as possible, allowing the operators to fully focus on marketing their online casino brand and generating traffic to the casino. In addition to Aspire Global’s B2B service offering, the Company operates several proprietary casino brands, such as Karamba and Hopa, based on the same operational setup and technical platform that is offered to partners. Advisors Pareto Securities is acting as Global Coordinator and Sole Bookrunner in connection with the Offering. Baker McKenzie is legal advisor to the Company as to Swedish Law. Herzog Fox Neeman is legal advisor to the Company as to Israeli law and regulatory matters. WH Partners are legal advisors to the Company as to Maltese law. Roschier is legal advisor to Pareto Securities. IMPORTANT INFORMATION This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by Aspire Global plc in any jurisdiction where such offer or sale would be unlawful. This announcement and the information contained herein is not for distribution in or into the United States, Australia, Canada, Japan, Israel or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States. In any EEA Member State, other than Sweden, that has implemented Directive 2003/71/EC as amended (together with any applicable implementing measures in any member State, the “Prospectus Directive”), this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive. In the United Kingdom, this announcement and the information that this announcement contains is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. Any offering of the securities referred to in this announcement will be made by means of a prospectus. This announcement is not a prospectus for the purposes of the Prospectus Directive. A prospectus prepared in accordance with the Prospectus Directive will be published and held available at www.aspireglobal.com. Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus. Certain matters discussed in this announcement may constitute forward-looking statements. Forward looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “intends”, “estimate”, “will”, “may”, "continue", “should” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. In connection with the offer or sale of securities referred to herein, the Global Coordinator may overallot securities/conduct stabilisation or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. Any stabilisation action or over-allotment will be conducted by the Global Coordinator in accordance with all applicable laws and rules.

Wood pellet imports to both South Korea and Japan close to record highs with a majority of the supply continuing to be sourced from Vietnam

Seattle, USA. Wood pellet imports to Asia reached an all-time-high in the 4Q/16 when Japan and South Korea together imported 630,000 tons of pellets. Although import volumes were down slightly in the 1Q/17, they were still over 40% higher than in the 1Q/16, as reported in the latest issue of the Wood Resource Quarterly (WRQ). South Korea is by far the main destination for pellets in Asia, and in 2016, the country was the world’s third largest importer of pellets, trailing only the United Kingdom and Denmark. Although import volumes to Japan have tripled from 2014 to 2016, the usage of pellets is still at a relatively low level (see WRQ for detailed trade data). Consumption of pellets in Japan and South Korea has increased quite rapidly the past four years because of new government requirements which favor reducing carbon emissions and increasing the usage of renewable energy. The recent trend in pellet usage is likely to continue in the future and is driven both by incentives (subsidies) and regulations (renewable energy portfolio standards). With an urgent need to replace nuclear energy and generous feed-in-tariffs, it is expected that Japan will increase importation of wood pellets quite substantially over the next five years. Vietnam has been the major supplier of pellets to the Asian market for the past three years, accounting for almost two-thirds of the shipments to Japan and South Korea in 2016. Canada was an early supplier to the Asian market, but its market share dropped from 22% in 2014 to 14% in 2016. However, in the 1Q/17, Canada increased shipments to Asia to the second the highest quarterly level on record and the market share was up to 21%. Import prices for pellets to South Korea fell dramatically from early 2014 to the summer of 2016, according to a recent WRQ Trade Snapshot report. The two-year long price decline ended in the 3Q/16, when prices slowly started to recover. The import prices continued their upward trend during the first four months of 2017 with Malaysian pellets increasing the most. Global lumber, sawlog and pulpwood market reporting is included in the 52-page quarterly publication Wood Resource Quarterly (WRQ). The report, which was established in 1988 and has subscribers in over 30 countries, tracks sawlog, pulpwood, wood chip, lumber and pellet prices, trade and market developments in most key regions around the world. To subscribe to the WRQ, please go to www.woodprices.com

Magnolia Bostad sells 325 apartments in Uppsala city centre

The buyer is Heimstaden Bostad and the sale is made through company transfers. The deal is Magnolia Bostads first with Heimstaden Bostad, which is a long-term and stable property owner. The property value at completion is estimated to approximately SEK 800 million. The Senapsfabriken project consists of a total of 1,800 homes divided into three phases, of which phase 1, comprising 455 apartments, was sold to SEB Domestica III in May 2016. NCC is signed as contractor and construction start is planned for the third quarter of 2018. Magnolia Bostad will develop and manage the project all the way through, until the homes are ready for occupancy, which is estimated to the second quarter of 2021. The project is centrally located in Uppsala's southern part, in the Kungsängen district, and is developed in the area of the old Slottsfabriken. Kungsängen is a neighborhood now undergoing a transformation from industrial area into attractive residential area. Residences are developed with a clear focus on sustainability and energy efficiency. For more information, please contact:Erik Rune, Vice President and Head of Business Development+46 73-399 40 30, erik.rune@magnoliabostad.se  Mikaela Senator, Investor Relations Manager+46 70-775 57 57, mikaela.senator@magnoliabostad.se  Magnolia Bostad develops efficient, attractive and functional residential properties, including rental apartments, tenant-owned apartments and hotels, in attractive locations primarily in Sweden’s growth areas. Our work is based on a holistic approach where the operations are conducted in a manner that promotes long-term, sustainable urban development. Magnolia Bostad's share (MAG) is listed on Nasdaq First North Premier. Erik Penser Bank is the Certified Adviser for the Company. More information is available at www.magnoliabostad.se

Analysguiden’s analysis is now available in English.

The analysis of Brighter AB, originally published by Analysguiden on the 15th of June 2017, is now available in an English translation. Read the full analysis at Analysguiden . For more information, please contact:Truls Sjöstedt, CEO                Tel: +46 709 73 46 00                Email: truls.sjostedt@brighter.se  Henrik Norström, COO                Tel: +46 733 40 30 45                Email: henrik.norstrom@brighter.se About Brighter AB (publ)    Brighter develops solutions for data-driven and mobile health services. Through its intellectual property and its first launch Actiste®, the company creates a more efficient care chain with focus on the individual. The goal is to simplify, streamline and enhance the information flow of relevant and reliable data between the patient and health care professionals. Brighter is initially focused on diabetes care, but there are opportunities in the future to operate on a broader level, spanning more diseases and treatment approaches. This is done through The Benefit Loop®, Brighter’s cloud-based service that continuously collects, analyzes and shares data on the user's terms. The Company's shares are listed on NASDAQOMX First North/BRIG . Brighter’s Certified Adviser on Nasdaq OMX First North is Remium Nordic AB +46 (0)8 – 454 32 50, CorporateFinance@remium.com, www.remium.com.

New Hybrid Operating Room in Getinge Experience Center, Germany.

June 26, 2017Rastatt, Germany Getinge is pleased to announce the opening of a new modern hybrid operating room (OR) in the Experience Center in Rastatt, Germany. The Hybrid OR – a surgical theatre equipped with advanced medical imaging devices – enables intraoperative 2D and 3D imaging during minimally-invasive surgery. The Getinge Experience Center (formerly the Getinge Showroom) is an international knowledge hub that presents a wide range of products and solutions within a complete, real-world medical setting. This center welcomes over 24,000 healthcare professionals per year. The new Hybrid OR is equipped with a combination of the new ARTIS pheno® robotic C-arm from Siemens Healthineers, the Maquet Magnus Operating Table and associated products (such as the Maquet Moduevo Ceiling Supply Units, soon to be installed). This facility creates a unique environment where visitors can envision the possibilities of intraoperative imaging. The Hybrid OR was officially opened on Tuesday 20 June 2017 by Frédéric Pette, Acting President Surgical Workflows, Getinge and Dr. Heinrich Kolem, President Advanced Therapies, Siemens Healthineers. Frédéric Pette shared the visionary nature of the partnership and the strong focus on research and development. “With Siemens Healthineers we have a partner that has enabled us to upgrade our Hybrid OR with the latest robotic C-arm on the market. The combination of ARTIS pheno® and Maquet Magnus is taking imaging to a new level. And this is just the beginning. Our strategic partnership will lead to more innovative solutions in the near future.” “The last five years of our partnership have shown us that Getinge and Siemens Healthineers share a common vision - bringing imaging systems, robotics and surgery together. Therefore it was an easy decision for us to install one of the first ARTIS pheno® here at Getinge’s Experience Center and make this vision accessible to our customers. It also underlines how valuable this partnership is to us.” Dr. Heinrich Kolem added. About ARTIS pheno® ARTIS pheno® is an angiography system delivering images for individualized preprocedural planning, intraoperative guidance, and immediate assessment. The unique floor-mounted robotic C-arm system allows patients to be treated in a hybrid operating room regardless of their size, condition, or positioning needs, meeting the significant challenges modern minimally invasive treatment poses to imaging systems. About the Getinge Hybrid OR Getinge is a market leader in the hybrid OR market, completing over 900 installations worldwide, and providing the complete range of products including operating tables, surgical lights, ceiling supply units, wall and ceiling elements, anesthesia units, heart-lung machines and OR integration. For further information, please contact Tracey Dawe Director Communications and Congress Management Europe, Middle East & Africa Phone: + 44 77 177 84965 Email: tracey.dawe@getinge.com About Getinge Getinge is a global provider of innovative solutions for operating rooms, intensive-care units, sterilization departments and for life science companies and institutions. Based on our first-hand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving every-day life for people, today and tomorrow.

AGREEMENT TO ACQUIRE MANOR FARM – THE LEADING CHICKEN PROCESSOR IN IRELAND

Scandi Standard AB (publ.) (SCST SS) is pleased to announce that it has entered into an agreement to acquire Manor Farm, the largest chicken processor, and market leader, in the Republic of Ireland (Ireland). The business had net revenues of EUR 164 million and EBITDA of EUR 13 million in 2016. The agreement values Manor Farm at an enterprise value, based on the closing price for the Scandi Standard shares on 26 June 2017, of EUR 94 million. Settlement will be a combination of 6 million Scandi Standard shares (“Consideration Shares”), an earn-out mechanism, cash and the assumption of outstanding interest-bearing debt. Completion of the transaction is subject to customary conditions, including approval of the issuance of the Consideration Shares at an Extraordinary General Meeting of Scandi Standard. The four largest shareholders, representing approximately 29% of Scandi Standard’s share capital, support the transaction. Transaction rationale · Profitable and well-run operations · Clear market leader in a market with strong preference for local produce · Capable and experienced management team with a strong track record · Tangible best practice opportunities identified · Significant EPS accretion · Attractive EV/EBITDA acquisition multiple · Post transaction leverage ratio unchanged · Risk diversification through a new geographical presence About Manor Farm Manor Farm sources and processes approximately 50% of all fresh chicken sold in the Irish retail market and approximately 25% of all chicken consumed in Ireland. The business focuses on fresh products for the retail market, selling to a diversified customer base. The business has its processing plant in Shercock in County Cavan. It has approximately 130 farmers contracted as growers and approximately 43 farmers contracted as breeders. It owns and operates a feed mill, which has revenues of approximately EUR 80 million and produces solely for its contracted growers. In the accounts, feed revenues will be eliminated from Manor Farm’s net revenues. The combined entity generated an EBITDA of EUR 13 million in 2016. Manor Farm employs approximately 850 people. Manor Farm is one of the oldest family businesses in Ireland, tracing its origin to 1775 when the founder, Peter Carton, set up a business in Dublin’s fruit and vegetable markets. Recognising the opportunity for a poultry market, he began trading in all forms of poultry. Since then, the Carton family have continued the business. In 1956, they opened a chicken processing plant in Dublin, introducing modern chicken products to the Irish market, and in 1970 they moved their business to a new custom-built processing plant, which has been expanded and upgraded continually since then. Vincent Carton and Justin Carton are the eighth generation of the family in the business. They succeeded their father, Thomas P. Carton, who was involved in the business for 69 years. Over the past generation, Vincent and Justin and their management team have worked closely with Irish retailers and farmers to create a stable and sustainable supply of Irish produced chicken that meets an increasingly discerning consumer demand. About the Irish poultry market The dynamics of the Irish poultry processing market are very similar to those in the Nordic markets. The market is well consolidated with three domestic players of scale. Manor Farm has a market share of about 50% for fresh chicken products sold through retail in Ireland. As in Scandi Standard’s existing markets, there is a strong preference for domestic produce in the retail channel, and the fresh segment is well developed. Importers distribute mainly to food service, butchers and industrial segments. The consumer market in Ireland is similar to the Nordic markets in terms of size, population and GDP. Leif Bergvall Hansen, CEO of Scandi Standard, states: “I am enthusiastic about the deal as Manor Farm satisfies all of our acquisition criteria. The company has profitability in line with our existing operations, is well run and is the clear market leader in chicken in the Irish retail market. With its capable and experienced management team, the business can be run with a high degree of autonomy whilst additional steps, which have been identified, can be taken to capture the benefits of best practice. As many of our risks are country specific, the acquisition is also likely to reduce our earnings volatility through diversification.” The transaction The deal values Manor Farm at EUR 94 million (Enterprise Value) based on Scandi Standard’s closing share price as of 26 June 2017 (SEK 52.5). Settlement is agreed to consist of the Consideration Shares, equivalent to 9.99% of the current share capital of Scandi Standard; four earn-out tranches with payments calculated on the basis of the EBITDA achieved by Manor Farm in 2017, 2018, 2019 and 2020 respectively, which have a nominal aggregate base amount of EUR 25.4 million; and the balance, EUR 36.3 million, in the form of cash payments and assumption of outstanding interest-bearing debt. Completion of the transaction is subject to customary conditions, including approval of the issuance of the Consideration Shares at an Extraordinary General Meeting of shareholders of Scandi Standard. The transaction is expected to close during the second half of Q3. The vendors of Manor Farm have agreed to a 12-month lock-up on the Consideration Shares commencing from their first day of trading. The first earn-out tranche of EUR 0.4 million will be paid if 2017 EBITDA exceeds EUR 13 million. The three later earn-out tranches, which have a nominal aggregate base amount of EUR 25 million, are subject to adjustment based on the actual EBITDA performance in each of the earn-out years 2018, 2019 and 2020 as compared to the 2016 EBITDA. For the calculation of each earn-out payment, a sliding EV/EBITDA multiple scale is applied, ranging from a minimum multiple of zero to a maximum multiple of 9. The earn-out tranches will be paid upon availability of audited accounts for the relevant year, verifying EBITDA. The agreement includes a provision whereby the vendors of Manor Farm would be eligible for a minimum of the base earn-out amount at maturity of each of the remaining earn-out tranches if there is a change of control in Scandi Standard. Manor Farm has a very experienced management team with a strong track record. Five members of the management team currently own 100% of Manor Farm, and as shareholders in Scandi Standard they will continue to lead and develop the business in alignment with the rest of the Scandi Standard group. Vincent Carton and Justin Carton, who currently hold 85% of the financial interest in Manor Farm, intend to remain as Scandi Standard shareholders over the longer term, and Vincent Carton has agreed to join the Board of Directors of Scandi Standard if proposed by the Nomination Committee and elected by the General Meeting. Leif Bergvall Hansen states: “We are also pleased that the financial criteria are met in terms of expected EPS accretion and an attractive acquisition multiple. Furthermore, the limited upfront cash consideration leaves our leverage ratio largely unaffected by the transaction, which is an important criterion in terms of allowing a competitive direct yield going forward. Finally, the transaction structure secures alignment of interests and clear incentives for management to further develop the business. We look forward very much to being part of the Irish food processing industry and to building on the strong relationships of Manor Farm in that market.” Vincent Carton, CEO of Manor Farm, states: “In considering a succession of ownership for our family business, my brother Justin and I have been determined to find a partner that can continue to build on our strong relationships with customers, employees, suppliers and the broader communities in which we operate. As the next generation of Cartons have chosen to pursue other business interests, we set out to find a partner with high standards, a culture similar to our own and the capability to develop the business to its fullest potential. We believe that Scandi Standard is the ideal partner, and we are delighted to have agreed a transaction structure that allows the current management to remain fully in place and that also allows the Carton family to become shareholders in Scandi Standard. We believe that this arrangement will serve our customers, employees, and suppliers well, and we look forward very much to the next chapter in the history of Manor Farm.”  Preliminary proforma figures and accounting matters  Transaction costs are estimated at a little over 2% of EV, including stamp duty of 1% of the purchase price. The identified improvement potential is partly reliant on capital expenditures and certain measures to align operations with industry best practice. The phasing of such investments and measures will be resolved on a case by case basis within the general planning framework of the Scandi Standard group, and be communicated and accounted for accordingly. Financing The payment of the purchase price will be financed by an issuance of six million shares in Scandi Standard and the cash payment and transaction costs will be financed by a combination of available cash and existing bank facilities. Extraordinary General Meeting (EGM) Scandi Standard’s Board of Directors will shortly call an EGM to seek approval for the transaction through a proposal to authorise the board to issue the Consideration Shares. The date for the EGM is planned to be on or about 15 August 2017. Scandi Standard has approached its four largest shareholders, representing a total of approximately 29% of the current share capital, who support the authorisation for the board to issue the Consideration Shares at the EGM. The EGM resolution will require approval from 2/3 of the votes cast and shares represented at the EGM. Issuance of the Consideration Shares The Board of Directors will resolve to issue the 6 million Consideration Shares following the EGM’s authorisation. The purpose of the issuance is to pay in part for the acquisition of Manor Farm and the shares will be subscribed for by the sellers of Manor Farm. The issuance will result in a share capital increase of approx. SEK 60,000. The issue price for the shares will be approx. EUR 36 million. The Consideration Shares are expected to be issued in connection with closing of the acquisition, i.e. in the second half of Q3. Presentation of the acquisition Scandi Standard will hold a presentation about the acquisition of Manor Farm on Tuesday 27 June 2017 at 09.30 CET. The presentation will be hosted by Leif Bergvall Hansen, CEO and Henrik Heiberg, Head of M&A, Financing and IR. Dial In numbers: Sweden 0850 510 036  United Kingdom 0800 368 0649All other locations + 44 20 3059 8125 The presentation used in the conference call will be published at http://www.scandistandard.com prior to the call. The conference call will also be audio webcasted in “listen-only” mode at the Scandi Standard website. For further information please contact: Leif Bergvall Hansen, CEO of Scandi Standard (+45 22 10 05 44)Henrik Heiberg, Head of M&A, Financing and IR, Scandi Standard (+47 917 47 724) This information is information that Scandi Standard AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 0730 CET on 27 June 2017. ABOUT SCANDI STANDARD AB (publ.) Scandi Standard is the largest producer of chicken-based food products in the Nordic region with leading positions in Sweden, Denmark, Norway and Finland. The company produces, markets and sells ready to eat, chilled and frozen products under the strong brands Kronfågel, Danpo, Den Stolte Hane and Naapurin Maalaiskana. In 2016 Scandi Standard produced approximately 130 million chickens, had net sales of 6,000 MSEK and 1.700 employees. In 2014 Scandi Standard was introduced on the Stockholm stock market. OECD has forecasted that half of the world's protein intake will come from chicken in the year of 2023. Several trends drive the demand, such as:  · Increased health consciousness · Superior environmental profile · Convenient and easy-made · Lower production costs than red meat Scandi Standards strategy for profitable growth is to drive organic growth, increase the cost effectiveness and make strategic acquisitions and partnerships. IMPORTANT INFORMATION This press release does not contain or constitute an invitation or an offer to acquire, sell, subscribe for or otherwise trade in shares or other securities in Scandi Standard. This press release has not been approved by any regulatory authority and is not a prospectus. This press release contains forward-looking statements which reflect Scandi Standard’s current view on future events and financial and operational development. Words such as "intend", "will", "expect", "anticipate", "may", "plan", "estimate" and other expressions than historical facts which imply indications or predictions of future development or trends, constitute forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties as they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from the forward-looking statements. The information, opinions and forward-looking statements concluded in this announcement speak only as of its date and are subject to change without notice.

Autoliv and Volvo Cars to team up with NVIDIA to develop advanced systems for self-driving cars

Autoliv and Volvo Car Corporation, with Zenuity, a newly-formed automotive software development joint venture equally owned by Autoliv and Volvo Car Corporation, will work together with NVIDIA to develop next generation self-driving car technologies, with a target to bring level 4 autonomous driving to the market by 2021. As part of the agreement Autoliv, Volvo, and Zenuity will use NVIDIA’s AI car computing platform as the foundation for their own advanced software development, bringing together two of the most respected companies in automotive safety with one of the world’s leading artificial intelligence companies. Jan Carlson, Chairman, President and CEO of Autoliv, said:  “We now have full access to the leading computing platform for autonomous driving. Autoliv, Volvo Cars and NVIDIA share the same vision for safe, autonomous driving. This cooperation will further advance our leading ADAS and autonomous driving product and solution offerings to the market.” “This cooperation with NVIDIA places Volvo, Autoliv and Zenuity at the forefront of the fast moving market to develop next generation autonomous driving capabilities and will speed up the development of Volvo’s own commercially available autonomous drive cars,” said Håkan Samuelsson, President and Chief Executive of Volvo Cars. Jensen Huang, Chief Executive of NVIDIA, said: “Artificial intelligence is the essential tool for solving the incredibly demanding challenge of autonomous driving. We are building on our earlier collaboration with Volvo to create production ready vehicles that will make driving safer, lead to greener cities and reduce congestion on our roads.” Autoliv, Volvo Car Corporation, Zenuity, and NVIDIA will work together to develop systems that can utilize deep learning -- a form of artificial intelligence -- to recognize objects in their environment, anticipate potential threats and navigate safely. These systems can compare real-time situational awareness with a known high-definition map, enabling them to plan a safe route and drive precisely along it, adjusting to ever-changing circumstances. They also perform other critical functions such as stitching camera inputs to create a complete surround-view of the car. The cooperation with NVIDIA will complement Zenuity’s existing mission to provide Autoliv autonomous vehicle related software to third party OEMs using Autoliv’s established and broad sales, marketing and distribution network and to provide Volvo Car Corporation with self-driving software for its own vehicles. Inquiries: Thomas Jönsson, Group Vice President Communications.          Tel +46 (0)8 58 72 06 27

Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity

Boston, U.S. and Lund, Sweden — 27 June 2017 — Rhythm and Camurus (NASDAQ STO:CAMX) today announced positive initial results from an ongoing Phase 1A clinical trial evaluating the pharmacokinetics and tolerability of an extended-release formulation of setmelanotide (RM-493), Rhythm’s novel melanocortin-4 receptor (MC4R) agonist in development for the treatment of rare genetic disorders of obesity. The new setmelanotide formulation uses Camurus drug delivery technology FluidCrystal® injection depot. Camurus has granted Rhythm a worldwide license to the FluidCrystal® technology to formulate setmelanotide and to develop, manufacture and commercialize this new formulation that has the potential for once-weekly dosing administered as a subcutaneous injection. Rhythm is developing setmelanotide for the treatment of obesity caused by genetic deficiencies in the MC4 pathway, a key biological pathway in humans that regulates weight by increasing energy expenditure and reducing appetite. This ongoing Phase 1A clinical trial is a double-blind, placebo-controlled, single-rising dose study to evaluate the pharmacokinetics and tolerability of three doses of setmelanotide extended-release formulation in healthy obese patients (BMI ≥ 30 kg/m2), with setmelanotide administered by subcutaneous injection. “The initial results from this first trial are impressive and meet our pharmacokinetics and tolerability criteria for a once-weekly formulation of setmelanotide,” said Dr. Keith Gottesdiener, Chief Executive Officer and Chairman of the Board of Directors of Rhythm. “We intend to develop this once-weekly formulation as a product line extension, to improve convenience for patients with genetic deficiencies in the MC4 pathway.” “Reducing the burden of daily injections and contributing to keeping the individual at a healthy weight, is an important step forward that may potentially provide patients with enhanced quality of life,” said Dr. Fredrik Tiberg, President and Chief Executive Officer of Camurus. The U.S. Food and Drug Administration (FDA) granted setmelanotide Breakthrough Therapy Designation (BTD) for the treatment of pro-opiomelanocortin (POMC) and leptin receptor (LepR) deficiency obesity. Results from Phase 2 clinical trials of setmelanotide demonstrated significant weight loss and substantial reductions in hunger for patients with POMC and LepR deficiency obesity. Rhythm recently initiated Phase 3 clinical trials for each of these indications. About SetmelanotideSetmelanotide is a potent, first-in-class MC4R agonist in development for the treatment of obesity caused by genetic deficiencies in the MC4 pathway – a key biological pathway in humans that regulates weight by increasing energy expenditure and reducing appetite. The critical role of the MC4 pathway in weight regulation was validated with the discovery that single genetic defects along this pathway result in early-onset and severe obesity. Rhythm recently initiated Phase 3 clinical trials of setmelanotide in POMC deficiency obesity and in LepR deficiency obesity. These are rare genetic disorders associated with severe, early-onset obesity and unrelenting hyperphagia caused by defects in the MC4 pathway that are upstream of MC4R. Initial efficacy data with setmelanotide demonstrate that it has the potential to restore lost function by activating the intact MC4 pathway below the genetic defect in these disorders. Rhythm is currently evaluating setmelanotide for the treatment of the following genetic disorders of obesity: POMC deficiency obesity, LepR deficiency obesity, Prader-Willi syndrome, Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity and POMC epigenetic disorders. About FluidCrystal® injection depotThe FluidCrystal® injection depot delivers therapeutic levels of drug substance over selected extended periods – from days to months – from a single injection. While traditional depot therapeutics comprise complicated microsphere technology, the FluidCrystal® injection depot offers a liquid solution that transforms into a controlled release liquid crystal gel matrix in situ on contact with minute quantities of aqueous fluid at the injection site. The FluidCrystal® delivery system overcomes traditional side effects associated with high initial drug release on injection (drug burst) and poor drug stability by effectively encapsulating the drug compound in the nanopores of the depot matrix throughout the entire process from injection until final degradation. This, together with the ready-to-use product design, makes the system highly suitable for sustained parenteral delivery of peptides and proteins. FluidCrystal® is a registered trademark of Camurus AB. About RhythmRhythm is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first-in-class MC4R agonist for the treatment of rare genetic disorders of obesity. Rhythm supports The Genetic Obesity Project (www.GeneticObesity.com), which is dedicated to improving the understanding of severe obesity that is caused by specific genetic defects. The company is based in Boston, Massachusetts. For more information, visit www.rhythmtx.com. About CamurusCamurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com. Media contactsFor Camurus:Fredrik Tiberg, President & CEOTel. +46 (0)46 286 46 92fredrik.tiberg@camurus.com Rein Piir, VP Investor RelationsTel. +46 (0)70 853 72 92ir@camurus.com For Rhythm:Adam Daley, Berry & Company Public RelationsTel. +1 212 253 8881adaley@berrypr.com The information was submitted for publication at 08.00 a.m. CET on 27 June 2017.

Aspire Global plc publishes prospectus in connection with its listing on Nasdaq First North Premier in Stockholm

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, ISRAEL OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE For the complete press release follow this link: https://www.aspireglobal.com/ipo For additional information, contact:Tsachi Maimon, CEOTel. +356 79 777 898e-mail: tsachi@aspireglobal.com Carl Klingberg, ChairmanTel. +46 708 898 989e-mail: carl.klingberg@aspireglobal.com About Aspire Global Aspire Global is a Business to Business (“B2B”) service provider for the online gaming market and offers its B2B partners a full-service solution for launching and operating online casinos. In addition, Aspire Global holds several local gaming licenses enabling its partners to fulfill their full potential. With more than ten years of operational experience in managing casino networks and developing in-house proprietary technology, Aspire Global offers an online gaming solution which ensures that every aspect of partners’ casinos, from regulation and compliance to payment processing, risk management, CRM, support and player value optimisation, runs as efficiently and effectively as possible, allowing the operators to fully focus on marketing their online casino brand and generating traffic to the casino. In addition to Aspire Global’s B2B service offering, the Company operates several proprietary casino brands, such as Karamba and Hopa, based on the same operational setup and technical platform that is offered to partners. Advisors Pareto Securities is acting as Global Coordinator and Sole Bookrunner in connection with the Offering. Baker McKenzie is legal advisor to the Company as to Swedish Law. Herzog Fox Neeman is legal advisor to the Company as to Israeli law and regulatory matters. WH Partners are legal advisors to the Company as to Maltese law. Roschier is legal advisor to Pareto Securities. IMPORTANT INFORMATION This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by Aspire Global plc in any jurisdiction where such offer or sale would be unlawful. This announcement and the information contained herein is not for distribution in or into the United States, Australia, Canada, Japan, Israel or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States. In any EEA Member State, other than Sweden, that has implemented Directive 2003/71/EC as amended (together with any applicable implementing measures in any member State, the “Prospectus Directive”), this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive. In the United Kingdom, this announcement and the information that this announcement contains is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”) or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “Relevant Persons”). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. Any offering of the securities referred to in this announcement will be made by means of a prospectus. This announcement is not a prospectus for the purposes of the Prospectus Directive. A prospectus prepared in accordance with the Prospectus Directive will be published and held available at www.aspireglobal.com. Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus. Certain matters discussed in this announcement may constitute forward-looking statements. Forward looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “intends”, “estimate”, “will”, “may”, "continue", “should” and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. In connection with the offer or sale of securities referred to herein, the Global Coordinator may overallot securities/conduct stabilisation or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. Any stabilisation action or over-allotment will be conducted by the Global Coordinator in accordance with all applicable laws and rules.

Developing fully biodegradable food packaging

Many Swedes purchase meat at least once a week. To ensure that the meat they buy retains its quality, packaging is required that meets the high sustainability and safety demands placed on foodstuffs. Svenskt Butikskött now wants to take this further and develop packaging that also lives up to the company’s own demands for ecological sustainability. This is why it has become involved in a new, major packaging project in cooperation with Södra. Renewable materials from forest raw materialDuraPulp has been developed by Södra from forest raw material. It is a biodegradable and renewable material that can replace fossil-based products. The material is stable, water resistant and highly durable. It is malleable and can be used for every type of product, from manufacturing materials to sophisticated design. "We are very pleased and excited about our new cooperation with Södra," said Thomas Östlund, owner of Svenskt Butikskött. "We are passionate about ecological sustainability and we hope that the new agreement will enable us to develop 100-percent biodegradable, fibre-based packaging for our products. Our current packaging solution is recyclable, but not biodegradable and compostable – which is not sufficient for a company with our ecological profile." "Both producers and consumers are demanding sustainable alternatives to packaging made from fossil-based materials like plastic," said Erik Bengtson, business developer at Södra. "This is where the forest and the forest industry have a lot to offer. We have a fantastic, renewable commodity and we have the knowledge and experience to develop new solutions that are required for a climate-smart future. DuraPulp is a 100-percent sustainable alternative that is well-suited for packaging intended for sensitive substances such as food." The agreement implies that the development and prototype production will commence already during the summer and is expected to be completed in the autumn. If there is a positive result for the prototype, the work will continue to pre-industrial production and initial customer testing before the end of the year. It is hoped to develop packaging that can already be used within about a year. For more information, please contact:Erik Bengtson, business developer, Södra,Tel: +46 (0)72-58 342 16Thomas Östlund, owner, Svenskt Butikskött,Tel: +46 (0)702-84 00 50 Södra’s Pressroom,Tel: +46 (0)470-890 90E-mail: press@sodra.com 

Compact cities and efficient land use with tower buildings

What are suitable or unsuitable locations for towers? It is a matter of opinion, but if any location is suitable, it is the new Pasila. This is the view of Juha Kostiainen, Senior Vice President of Sustainable Urban Development and Harri Isoviita, Senior Vice President of Residential Construction at YIT. What makes Pasila a good place for high-rise buildings? Juha Kostiainen bases his opinion on the fact that Pasila has been surrounded by wasteland. The eastern side is home to concrete buildings from the 1970s, to which higher buildings would create a nice contrast. “The railway yard will require substantial construction efforts, it won’t be possible to change the look with just small measures.” Towers would change the entire nature of Pasila,” says Kostiainen. He notes that three large building complexes are currently being built in Tripla in the centre of Pasila. “It would be downright embarrassing to build three-storey buildings next to them. Tripla’s urban landscape requires expressivity.” According to Harri Isoviita, the pace of urbanisation is increasing. High-rise buildings have been noted as a good solution around the world, why not in Finland? A tower area is currently being planned for central Pasila. Decisions on the planning and implementation will be made in autumn 2018. In the reference plan, the highest tower has 40 storeys. Energy-efficient construction Kostiainen notes that smart cities build different urban environments. The Empire-style centre should be preserved as a historical part of Helsinki, while new one-family houses are suitable for areas located further away from the centre and closer to nature. In some parts of the city, urban, high-rise buildings can be very attractive. Manhattan is a good example of this. “When used in moderation, high-rise buildings give the city character, a profile and make it identifiable.” In a smart city, people who value different things can find different environments that please them. Diversity and different layers make areas more interesting. The indisputable plus side of high-rise buildings is its area density, which is especially needed when plots are scarce. “Finland’s is sparsely inhabited, which is a problem. Services are far away, and as a result, you need to use a car to get form point A to point B and, at the same time, people wonder why services are not available closer by.” Density is an urban feature. Kostiainen states that the general plan of Helsinki takes this account quite well, while also addressing future possibilities. “The direction of construction should not be further away but rather inwards, complementing the city. Not everything has to be low, and offering people different alternatives is always a good idea.” Another positive aspect of high-rise buildings is their energy-efficiency, as infrastructure benefits from having a large number of people in a small area. Thanks to high-rise buildings, it is also possible to improve the efficiency of land use in the rail traffic station areas. In addition, towers become landmarks that companies can utilise when building their image. Building towers has its own rules How is high-rise building different when compared to more conventional construction projects? Isoviita immediately comes up with a long list of differences. He has practical experience on the subject, for example from the Cirrus building in Vuosaari, Helsinki. “High-rise buildings require solid expertise from the designers. There are different official requirement classes, and for high-rise building, the highest class applies.” The City of Helsinki has prepared guidelines for high-rise building, applicable to buildings with more than 16 storeys. As an example, Isoviita mentions that for the structural design of high-rise buildings, an inspection conducted by an external party is required. In other words, the design work of an agency is inspected by another agency to ensure that there are no human or other errors in the plans. For instance, the exit routes of high buildings must be carefully considered. There are specific guidelines for lifts, and designers must be aware of them. There are also several instructions concerning fire safety, including sprinklers and smoke venting. “Sprinklers are the most effective way to stop fire from spreading. Apparently there were no sprinklers in the tower building in London,” says Isoviita in reference to the recent disaster. In addition, the tower buildings will be equipped with two smoke-protected exits. Furthermore, there are fire collars in the bushings between floors. The material stops the spread of fire from one floor to another. The designers must also be familiar with increasing water pressure: people will want to shower even on the top floor. In addition, the construction work itself is subject to guidelines that aim at preventing risks. The impact that the towers have on the wind and shade conditions must be taken into account. For example, the Finnish Meteorological Institute participated in the development of the Cirrus building by conducting wind analyses. The special requirements of high-rise building are costly, but how much they exceed the costs of an ordinary building always depends on the project. Isoviita explains that it is easier to design and build a straight, vertical building than one that narrows and widens like an hourglass. “However, the height of towers is already an international competition. It is becoming increasingly common for towers to be built as hybrid projects, with a single building comprising business premises, offices, a hotel and apartments. This means the surrounding area is also lively during evenings and weekends and infrastructure can be utilised more efficiently,” Isoviita explains. High-rise buildings Buildings that clearly deviate from the surrounding building stock and are visible from far away. They affect the silhouette of a city. The Helsinki High Rise competition will be organised to find a high-quality plan for the tower area planned for Pasila. According to the reference plan, the tower buildings in Pasila must have at least 15 storeys. Further information: Harri Isoviita,  Senior Vice President, Residential Construction, YIT Construction Ltd, tel. +358 40 553 3833, harri.isoviita@yit.fiJuha Kostiainen, Senior Vice President, YIT Corporation, tel. +358 400 721 475, juha.kostiainen@yit.fiHanna Malmivaara, Vice President, Communications, YIT Corporation, tel. +358 40 561 6568, hanna.malmivaara@yit.fi YIT creates a better living environment by developing and constructing housing, business premises, infrastructure and entire areas. Our vision is to bring more life into sustainable cities. We want to focus on caring for customers, visionary urban development, passionate execution and inspiring leadership. The engine of our growth is urban development involving partners. We operate in Finland, Russia, the Baltic countries, the Czech Republic, Slovakia and Poland. In 2016, our revenue amounted to nearly EUR 1.8 billion and we employ about 5,300 employees. Our share is listed on Nasdaq Helsinki.www.yitgroup.com  

Combination of Lindorff and Intrum Justitia completed creating the industry leading provider of credit management services

Today, June 27th 2017, the combination of Intrum Justitia and Lindorff has been closed. All subsidiaries of Lock TopCo AS (parent company of the Lindorff Group) are fully owned by Intrum Justitia AB (publ). CEO & President of the combined business will be Mikael Ericson, as communicated on June 9th 2017. On June 12th 2017 the European Commission approved the combination of Intrum Justitia and Lindorff. The approval is conditional upon the divestment of Lindorff’s operations in Denmark, Estonia, Finland and Sweden as well as Intrum Justitia’s operations in Norway, as communicated on May 18th 2017. The combination of Intrum Justitia and Lindorff creates a leading provider of credit management services (CMS) with local presence in 23 markets across Europe and a team of around 8,000 employees that are committed to promote a sound economy. “This is a milestone, not only for these two great companies, but for all of the CMS industry. By joining forces, both local and global clients will benefit from our pan-European platform, enhanced service offering, innovative solutions and best in class compliance. I am truly excited that we have come to this day and I really look forward to leading this company,” says Mikael Ericson, CEO & President of the combined company. "I am very pleased that the combination of these two strong companies has now been completed. Together, Intrum Justitia and Lindorff will form a market leader that will be able to deliver significant value to clients, shareholders and society by creating a very well-positioned and respected player in our industry both in terms of skill and geographic spread," says Lars Lundquist, Chairman of the Board in Intrum Justitia. "This combined company will be a leading force in shaping the future of credit management services. Nordic Capital looks forward to continuing to support the combined business as a listed company and sees strong potential for further value creation," says Kristoffer Melinder, Managing Partner, NC Advisory AB, advisor to the Nordic Capital Funds. In connection with the completion of the transaction, the current Board of Directors in Intrum Justitia has, by using the authorization of the Extraordinary General Meeting of December 14th 2016, resolved to issue 59,193,594 new shares at a subscription price of SEK 296.70 per share to the owners of Lindorff, after which they own 45% of the shares in Intrum Justitia, as announced in December 2016. In connection with the share issue Intrum Justitia has issued a prospectus, which will be approved by Finansinspektionen around 28 June 2017. The prospectus will be published on Intrum Justitias website, www.intrum.com. Lindorff will be consolidated into the financial statements of Intrum Justitia from 30 June  2017. This information was submitted for publication, through the agency of the contact person set out below, at 09.30 CET on 27 June 2017. For more information, please contact: Annika Billberg, Communications DirectorTel: + 46 702 67 97 91 About Intrum Justitia:Intrum Justitia offers comprehensive services, including purchase of receivables, designed to measurably improve clients’ cash flows and long-term profitability. Founded in 1923, Intrum Justitia has some 4,200 employees in 21 markets. Consolidated revenues amounted to SEK 6.1 billion in 2016. Intrum Justitia AB is listed on Nasdaq Stockholm since 2002. For further information, please visit www.intrum.com About Lindorff:Lindorff has been in the business of helping people manage credit for over 100 years. Its headquarters are located in Oslo, Norway, the same city as Eynar Lindorff founded the company back in 1898. Today it has 4,400 people in 12 countries across Europe helping customers back to a life of sustainable spending. Nordic Capital Fund VIII is a majority shareholder in the company which offers services within debt collection and debt purchase as well as payment and invoicing services. In 2016 Lindorff generated EUR 647 million in net revenue (2015 EUR 534 million). For further information, please visit www.lindorff.com  About Nordic Capital:Nordic Capital private equity funds have invested in mid-market companies primarily in the Nordic region since 1989. Through committed ownership and by targeting strategic development and operational improvements, Nordic Capital enables value creation in its investments. The Nordic Capital Funds invest in companies in northern Europe and in selected investment opportunities internationally. The most recent fund is Nordic Capital Fund VIII with EUR 3.5 billion in committed capital, principally provided by international institutional investors such as pension funds. The Nordic Capital Funds are based in Jersey, Channel Islands, and are advised by the NC Advisory entities in Sweden, Denmark, Finland, Norway, Germany and the UK. For further information about Nordic Capital please see www.nordiccapital.com    

Precise Biometrics launches ground-breaking spoof and liveness detection solutions to protect mobile payments

60 percent of all transactions are expected to be performed via biometric authentication by 2020, primarily via fingerprint sensors in mobile devices, according to the Biometrics Research Group. Spoof and Liveness detection, the real-time ability to determine if a finger is genuine and not fake, will become a necessity to secure mobile payments from fraud and identity theft. A one-of-a-kind security suitePrecise Biometrics’ solutions and services for efficient spoof and liveness detection is designed to protect fingerprint sensors which are vulnerable to spoofing via fake fingers. The main feature in the security suite is the integration of spoof and liveness detection capability into Precise Biometrics’ fingerprint software for mobile devices, Precise BioMatch™ Mobile .The anti-spoof solution is software-based, which makes it easy to integrate without any need for additional hardware and makes the solution cost-efficient. Furthermore, the solution works with any type of sensor on the market and is upgradeable to keep pace with emerging spoof threats. The software utilizes machine learning, making it adaptable to detect any form of spoof attempts. Precise BioMatch Mobile with spoof and liveness detection capabilities will be available by the end of Q3. “This is the first solution that offers fingerprint matching and liveness detection combined in a single software-based product, enabling easier integration at a lower cost compared to hardware-based solutions. By adding the other features in our security suite, we are offering our customers a one-of-a-kind toolbox for secure fingerprint technology, enabling trustworthy mobile payments,” said Håkan Persson, CEO of Precise Biometrics.The security suite also contains products and services to improve the spoof detection capabilities of fingerprint technology. The following products and services are already available and in demand in the market:   · Vulnerability analysis of fingerprint sensorsPrecise Biometrics offers assessment of a given fingerprint sensor’s vulnerability to spoofing via spoof attacks, analysis and a subsequent comprehensive report.  · Database Collection ServicesLive & Spoof fingerprint image collection to create databases and to train algorithms to improve fingerprint matching or spoof and liveness detection.   · Fingerprint Spoof LabA time-saving turnkey kit for building spoof resistance in fingerprint sensors. The kit contains guidelines and information about spoof creation, spoof specimens and lab supplies, as well as a user guide, for testing and evaluating sensor vulnerability.  The sensor technology manufacturer VKANSEE is licensing both Precise BioMatch Mobile and Precise Biometrics spoof and liveness detection solution. “The combination of efficient fingerprint matching technology with cutting edge spoof detection will bolster our already aggressive solution to prevent fraud from security vulnerabilities and guard against unauthorized access,” said Jason Chaikin, President of VKANSEE.  Read more about Precise BioMatch Mobile Read more about our Spoof and liveness detection FOR FURTHER INFORMATION AND INTERVIEWS, PLEASE CONTACTHåkan Persson, CEO, Precise Biometrics ABPhone: +46 46 31 11 05 or +46 734 35 11 05E-mail: hakan.persson@precisebiometrics.comABOUT PRECISE BIOMETRICSPrecise Biometrics is a market-leading supplier of solutions for convenient and secure authentication of people’s identity. We develop and sell fingerprint software and mobile smart card readers that provide the market’s best user experience and security. Our solutions are used hundreds of millions of times every day by people all over the world and are marketed together with strong business partners. For more information, please visit: precisebiometrics.com Follow us on LinkedIn  and Twitter . 

Triton has signed an agreement to acquire univativ

Frankfurt / Darmstadt (Germany), 27 June 2017 – An affiliate of Triton Partners ("Triton") has signed an agreement to acquire univativ Group (“univativ”), a leading German provider of specialized personnel services. Terms of the acquisition were not disclosed. The transaction is subject to regulatory approval in relevant jurisdictions and is expected to close following receipt of those approvals.   "We look forward to supporting univativ’s management and employees as a stable owner by investing in and supporting the growth and development of the company. Business Services is one of our core sectors where we have built substantial expertise and look forward to working together with the management team and board in building an even stronger company", said Peder Prahl, the Managing Partner of Triton Partners. "univativ Group, as one of the market leader in German speaking Europe, has been building its current presence over the last 20 years. This transaction is an important milestone, enabling us to continue with our strategic efforts. We welcome Triton as a new majority owner and a respected investor who will support us in developing innovative services and executing our plans for further expanding our market positions”, said Martin Ilg, Henning Loof and Olaf Kempin, who are the founders and Managing Directors of univativ. “univativ is a great company with an impressive growth profile and the team is looking forward to partner with management in an effort to further grow the firm. We are happy to see that our recently established dedicated smaller mid cap team has already signed its second acquisition”, added Andi Klein, Investment Advisory Professional and an advisor to the Triton Funds. About univativ Groupunivativ Group consists of two core brands: univativ and provativ. univativ, a personnel service provider that specialises in placing young professionals, has been successfully providing student specialists to more than 250 customers in all sectors. Its talent pool includes around 7,000 students and graduates at around 60 renowned universities. With 14 branch offices in Germany and Switzerland, univativ employs more than 1,200 people. provativ is a personnel service provider that specialised in the placement of experienced, freelance IT experts. provativ has two branches in Germany. For more information: www.univativ.com and www.provativ.de About TritonTriton Partners seeks to invest in and support the positive development of medium-sized businesses headquartered in Europe, focusing on businesses in the Industrial, Business Services and Consumer/Health sectors.  Triton Partners seeks to contribute to the building of better businesses for the longer term. Triton Partners and its executives strive to be agents of positive change towards sustainable operational improvements and growth. The 29 companies currently in Triton's portfolio have combined sales of around €13.9 billion and around 86,000 employees. Triton Partners has dedicated teams of professionals based in Germany, Sweden, Norway, Finland, Denmark, Italy, the United Kingdom, the United States, China, Luxembourg and Jersey. For further information: www.triton-partners.com  Press Contacts: univativStefanie SuffelPhone: +49 6151 850 45 61 TritonMarcus Brans                                                 Phone: +49 69 921 02204 

NeuroVive and Yungjin Pharm start clinical development in genetic mitochondrial disease

The study is a double-blind, placebo-controlled, single-dose, dose-escalation phase I clinical study to investigate the pharmacokinetics and safety/tolerability of KL1333 in healthy subjects. The study is planned to encompass a total of 60 healthy volunteers and will be fully performed by Yungjin Pharm. KL1333 is in development for the treatment of genetic mitochondrial diseases, such as MELAS and Kearns-Sayre syndrome, for which there are no current medicines. “This is a valuable milestone in our goal to offer patients with genetic mitochondrial disease a new treatment option. Furthermore, it is an important starting point in our collaboration with Yungjin Pharm”, said Erik Kinnman, CEO of NeuroVive. “We visited the clinical site just a couple a weeks ago and were very impressed by their extensive experience and professionalism in handling early clinical phase studies”, said Magnus Hansson, Chief Medical Officer of NeuroVive. The principal investigator for the study is Professor Kyung-Sang Yu MD, PhD at the Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine. “We are excited about the collaboration with NeuroVive, and the initiation of this clinical program is a significant step forward in the development of innovative medicines in this area with great medical needs”, Su Jun Park, CEO of Yungjin Pharm. On 2 May 2017, Yungjin Pharm granted NeuroVive exclusive global rights to develop and commercialize KL1333, except in Korea and Japan, where Yungjin Pharm retains full rights. Both companies will continue to develop KL1333 in their respective markets, primarily for the treatment of genetic mitochondrial disorders. NeuroVive plans to initiate a complementary European and/or US based phase I study in early 2018. For further information about the study, please visit: https://clinicaltrials.gov/ct2/show/NCT03056209 For investor relations and media questions, please contact:Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com NeuroVive Pharmaceutical AB (publ)Medicon Village, SE-223 81 Lund, SwedenTel: +46 (0)46 275 62 20 (switchboard)www.neurovive.com Notes to editors About KL1333 KL1333 is a potent modulator of the cellular levels of NAD+, a central coenzyme in the cell’s energy metabolism. KL1333 has in preclinical studies been demonstrated to increase mitochondrial energy output, reduce lactate accumulation, diminish the formation of free radicals, and to have long-term beneficial effects on energy metabolism. It is in clinical development stage for chronic oral treatment of primary genetic mitochondrial disorders such as MELAS, KSS, CPEO, PEO, Pearson, MERRF and Alpers syndrome. Its mode of action is complementary to that of NVP015, which is intended to alleviate acute episodes of energy crises in genetic mitochondrial disorders with dysfunction in respiratory complex I and to NVP025, intended to protect the mitochondria in skeletal muscle from dysfunctional calcium handling and consequential muscle wasting. About Mitochondrial Diseases Approximately 12 in every 100,000 people suffer from a genetic mitochondrial disorder. Mitochondrial disorders usually present in early childhood. KL1333 qualifies for orphan drug designation in the US and Europe during clinical development, enabling a faster and less costly route to market, and a higher price. In 2016, the orphan drug market amounted to USD 114 billion and in the same year, the average annual cost for the treatment of a single patient was an estimated USD 140,443 (approx. 1.3 million SEK).1 1 Evaluate Pharma Orphan Drug Report 2017 About Yungjin Pharm Yungjin Pharm Co. Ltd., established in 1952, has been playing a major role as a forerunner in the Korean pharmaceutical industry for half a century. With the inspiring mission statement, "To relieve the suffering of mankind from diseases with our innovative, effective and safe pharmaceutical products", they have shown a successful contribution not only within Korea, but also through global expansion. As a result, they have received a total of 25 awards including the President Award for Superior Product Development, the Prime Minister Award, Industry Award and many more. These accomplishments demonstrate their sustainability and commitment to the development of innovative products and business excellence in both overseas and domestic segments. The company is listed on the South Korean stock market, KOSPI (KRX 003520). About NeuroVive NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333). The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company’s strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:30 a.m. CEST on 27 June 2017.

Successful prediction of Cancer response to LiPlaCis® in Breast cancer and other tumors by OV’s DRP™ – strong support for randomized Phase 2

“If these early results hold in the completed Phase 2 in Breast Cancer, LiPlaCis would be of substantial benefit to those patients predicted sensitive,” Said Peter Buhl Jensen, Adjunct professor, MD, PhD and CEO of Oncology Venture. “The aim is to develop new effective treatment options for patients with hard to treat cancers guided by our Drug Response Predictor - DRP. Our results support that the LiPlaCis DRP is broadly applicable in Breast Cancer and across several cancer types,” Commented Peter Buhl Jensen “Cisplatin is one of the most active anticancer agents ever developed and LiPlaCis is developed as a new improved cisplatin which we can use with precision for the individual patient. We are of course aware that these are early results which need further validation but they do give us good hope for the ongoing and continued studies of LiPlaCis,” Peter Buhl Jensen further commented.  Data Oncology Venture has now completed analysis of those patients - where tumor tissue was available -  from the dose escalation phase of the LiPlaCis Phase 1/2 trial. A total of 11 patients have been analyzed whereof 3 patients from the Phase 2 part have been included. Patients in ongoing LiPlaCis treatment are not included in the analysis. Of the 11 patients with mixed tumor types (where 8 come from the dose escalation cohort) 2 patients had a Partial Remission (PR) and 4 patients had Stable Disease (SD). The correlation between prediction and response to treatment was 0.5 with a one-sided p-value of 0.06. Due to the small number of patients and mixed tumor types, this is a successful validation of the DRP’s ability to predict response. These early data suggest that patients predicted sensitive to LiPlaCis (top third) have a 67% probability of response, and a median of 18 weeks to progression. Strong support of randomized Phase 2 in Breast Cancer The above data supports the ongoing LiPlaCis development in collaboration with Cadila Pharmaceuticals LTD (“Cadila”) and Smerud Medical Research. Oncology Venture entered a collaboration agreement with Cadila. Cadila invest in kind i.e. in research and development activities of 310 cancer patients and DRP screening of more than 1400 patients. Cadila will perform four (4) Phase 2 trials in Prostate, Head & Neck, Skin and Esophageal cancers and a pivotal randomized clinical Phase 3 trial in metastatic Breast Cancer. A total of 18 million SEK has, as previously communicated, been granted to OV’s LiPlaCis project by Oncology Ventures partner Smerud Medical Research and the EUROSTARS program and Oncology Venture and Smerud now starts the preparation of a randomized Phase 2 in Breast Cancer which is expected to include other European countries. LiPlaCis® Phase 2 for metastatic Breast Cancer (mBC) LiPlaCis is an intelligent targeted liposomal formulation of cisplatin. LiPlaCis has finalized the dose escalation part of the trial and has demonstrated promising activity in patients already in the dose escalation part. LiPlaCis™ is administered intravenously in 3 week cycles on day 1 and day 8. Upon the investigator’s judgement, the patient may continue treatment for more than 3 cycles when benefitting from the study. Response (confirmed PR = Partial Response) has been published for the first DRP-screened patient with a hard to treat metastatic Breast Cancer. LiPlaCis has received status as a phase 2 study by the Danish authorities and i.e. 3 out of 4 in total Danish centers are now active in recruiting 12-15 metastatic Breast Cancer patients screened and expected to be highly likely responders to LiPlaCis. Phase 2 study in metastatic Breast Cancer expected to finalize recruitment in Q3 2017. LiPlaCis® has been registered together with its DRP™ companion diagnostic for an EU-marking. Next step in the regulatory strategy is building a data package for a ‘Pre-Submission meeting’ with the FDA. This is done in collaboration with US-experts. About the Drug Response Predictor - DRP™ Companion Diagnostic Oncology Venture uses the Medical Prognosis Institute (MPI) multi gene DRP™ to select those patients that by the genetic signature in their cancer is found to have a high likelihood of response to the drug. The goal is to develop the drug for the right patients and by screening patients before treatment the response rate can be significantly increased. This DRP™ method builds on the comparison of sensitive vs. resistant human cancer cell lines including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. The DRP™ is based on messenger RNA from the patients biopsies. The DRP™ platform i.e. the DRP™ and the PRP™ tools can be used in all cancer types, and is patented for more than 70 anti-cancer drugs in the US. The PRP™ is used by MPI for Personalized Medicine. The DRP™ is used in Oncology Venture for drug development.   For further information, please contact Ulla Hald Buhl, COO and Or Peter Buhl Jensen, CEOChief IR & Communications Mobile: +45 21 60 89 22Mobile: +45 2170 1049 E-mail: pbj@oncologyventure.comE-mail: uhb@oncologyventure.com About Oncology Venture Sweden AB Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient. The current product portfolio: LiPlaCis® for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma. Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates and Danish OV-SPV 2 will test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor.   This information is information that Oncology Venture Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on June 27th, 2017

Police Simulator 18

Moenchengladbach/Germany, June 27,  2017 – Dazzling blue lights, high-speed emergency drives and exciting investigative work: Last August publisher astragon Entertainment and Portuguese developer Big Moon Entertainment first announced a new police simulation game, which will let players experience the exciting day-to-day policework of a real US police officer, under the working title Police Simulator – Law Enforcement. Today, astragon is very happy to show some first screenshots of the game which will be released as Police Simulator 18 in retail and as digital download at the end of 2017. In Police Simulator 18 the player will slip into the role of a real US police officer – either male or female – and discover the interesting challenges and varied tasks that lie waiting for him in the streets of the sprawling US city of Loston Bay. The player can choose to go on patrol through three different city districts either alone in the game’s single player mode or together with a friend in the cooperative two-person multiplayer mode. The extremely expansive -  and thanks to the use of the Unreal® Engine 4 very lifelike – metropolis can be freely explored by the player either on foot or in one of three distinct patrol cars. In addition to these police cars with their fully functional cockpits the virtual cop will of course also be able to use a broad range of authentic police equipment such as safety vests, handcuffs, flashlights, firearms and more. Police Simulator 18 will be released for PC at the end of 2017. More information about the game will be coming soon. Further information about the development of Police Simulator 18 will also be available on Facebook:  https://www.facebook.com/PoliceSimulator18/ ______________________________________________ Unreal, Unreal Engine, the circle-U logo and the Powered by Unreal Engine logo are trademarks or registered trademarks of Epic Games, Inc. in the United States and elsewhere. All titles, content, publisher names, trademarks, artwork, and associated imagery are trademarks and/or copyright material of their respective owners. All rights reserved. ______________________________________________

EMA approves the potential to dose every 14 days or longer in updated dosing regimen for Alprolix®

Swedish Orphan Biovitrum AB (publ)  (Sobi™) has received approval from the European Medicines Agency (EMA) to update the dosing information for Alprolix® (eftrenonacog alfa). Alprolix is indicated for treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency), and it can be used for all age groups. The dosing information in the product information now includes that patients on long-term prophylaxis to protect against bleeding and who are well controlled on a 100 IU/kg once every 10 days regimen, might be treated on an interval of 14 days or longer.   “We are very pleased with the approval of the updated dosing regimen for Alprolix that offers the potential to extend the dosing regimen to 14 days or longer based on patient’s response. We are committed to improving the lives of people with Haemophilia B, and consider this an important step forward to reduce the treatment burden”, says Milan Zdravkovic, Senior Vice President, Chief Medical Officer and Head of Research & Development at Sobi._____ About Alprolix®Alprolix® (eftrenonacog alfa) [Coagulation Factor IX (Recombinant), Fc Fusion Protein], is a recombinant clotting factor therapy developed for haemophilia B using Fc fusion technology to prolong circulation in the body. It is engineered by fusing factor IX to the Fc portion of immunoglobulin G subclass 1, or IgG1 (a protein commonly found in the body), enabling Alprolix to use a naturally occurring pathway to extend the time the therapy remains in the body (half-life). While Fc fusion technology has been used for more than 15 years, Bioverativ and Sobi have optimized the technology and are the first companies to utilize it in the treatment of haemophilia. Alprolix is manufactured using a human cell line in an environment free of animal and human additives. Alprolix is approved and marketed by Bioverativ for the treatment of haemophilia B in the United States, Japan and Canada. It is also approved in Australia, New Zealand, Brazil and other countries, and Bioverativ has marketing rights in these regions. It is also authorised in the European Union, Iceland, Liechtenstein, Norway and Switzerland, where it is marketed by Sobi. Allergic-type hypersensitivity reactions and development of inhibitors have been observed with Alprolix in the treatment of haemophilia B, including in previously untreated patients. Note that the indication for previously untreated patients is not included in the EU Product Information.  About haemophilia BHaemophilia B is caused by having substantially reduced or no factor IX activity, which is needed for normal blood clotting.[i]  The World Federation of Hemophilia estimates that approximately 28,000 people are currently diagnosed with haemophilia B worldwide.[ii]  People with haemophilia B may experience bleeding episodes in joints and muscles that cause pain, decreased mobility and irreversible joint damage. In the worst cases, these bleeding episodes can cause organ bleeds and life-threatening haemorrhages. Injections of factor IX temporarily replace clotting factors necessary to resolve bleeding and, when used prophylactically, to prevent new bleeding episodes.i  About the Bioverativ and Sobi™ collaborationBioverativ and Sobi collaborate on the development and commercialisation of Alprolix and ELOCTATE/Elocta. Bioverativ has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory, and has manufacturing responsibility for ELOCTATE and Alprolix. Sobi has final development and commercialization rights in the Sobi territory (essentially Europe, North Africa, Russia and most Middle Eastern markets).Bioverativ was created as a spin-off from Biogen’s hemophilia business and separated from Biogen effective February 1, 2017. Bioverativ is an independent, publicly-traded company, headquartered in Waltham, Massachusetts, USA. During a temporary, transition period, which includes time to allow Bioverativ to establish certain licenses and consents related to ELOCTATE® and ALPROLIX, each of Bioverativ and Biogen will have a relationship to the products. About Sobi™Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016 Sobi had total revenues of SEK 5.2 billion (USD 608 M) and about 760 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.  For more information please contact Media relations Investor relations SobiSobi          Linda Holmström, Senior Jörgen Winroth, ViceCommunications Manager  President, Head of Investor Relations+ 46 708 73 40 95, + 46 +1 347 224 0819, +1 212 5798 697 31 74   0506, +46 8 697 2135linda.holmstrom@sobi.com jorgen.winroth@sobi.com  ---------------------------------------------------------------------- [i]  World Federation of Hemophilia. About Bleeding Disorders – Frequently Asked Questions. Available at: http://www.wfh.org/en/page.aspx?pid=637#Difference_A_B. Accessed on: January, 13, 2017. [ii]  World Federation of Hemophilia. Report on the Annual Global Survey 2013. Available at: http://www1.wfh.org/publications/files/pdf-1591.pdf. Accessed on: January 13, 2017. 

Corix Utility Services selects IFS Field Service Management for utilities maintenance and operations contracting

Across the United States and Canada, CORIX Utility Services (Corix) provides end-to-end metering infrastructure installations and supports field services for its customers, from meter and collector deployments, to meter reading, repair, and maintenance, to call center operations. From small to large scale projects, this requires complex planning and logistics management, as well as constant communications, to deliver a positive customer experience and satisfactory customer service to its clients, their customers and key stakeholders. Corix’s commitment to delivering the highest standard of service to its utility customers was a primary reason the company selected IFS Field Service Management software along with IFS Planning and Scheduling Optimization . Schedule optimization will not only help Corix increase the predictability of arrival times for its technicians—it will also ensure the assigned technician has the skills, tools and materials required to meet emerging needs in the field as they arise. “Scheduling was an important consideration for us because Corix takes the rate payer customer experience very seriously,” said Kevin Meagher, Corix Sr. Vice President of Utility Services North America. “We wanted field service management software that was always optimizing our schedule, so when emergent calls came in, the schedule would adjust automatically to ensure the right tech with the right skills arrives at the right time, with the right tools and materials to complete each job. Every time a customer calls for service, our new software will run more than 1,000 possible scenarios and pick the optimal way to deliver that service. That will help ensure customers’ experience will consist of making one call and getting one answer about their expected service timeline.” IFS Vice President of Sales in North America Mike Lorbiecki added, “Organizations like Corix need powerful service scheduling, but they also need so much more, including the ability to manage inventory, serial traceability of their customer’s assets and other devices, as well as repairs that go into customer applications. IFS Field Service Management offers the capabilities all the way along the service value chain necessary to deliver great service.” Learn more about how IFS supports service organizations here: www.ifsworld.com/corp/industries/service-providers/.

Eltel divests part of its Communication business in Poland

Today Eltel has signed and closed an agreement with Polish BKJ sp. z o.o. to sell its telecom maintenance service operations in Poland. These operations comprise maintenance of copper networks to the Polish telecommunication operator Orange. In 2016, net sales of these operations amounted to approximately EUR 24 million and employed approximately 950 people. The operations had only marginal impact on Group profitability in 2016. Following the transaction, Eltel will record a capital loss of approximately EUR 1.0 million affecting the EBITA result in the second quarter. This transaction aims to provide better opportunities for Communication to focus on the well performing upgrade operations that show good growth opportunities, especially within the fibre and mobile businesses. Following this transaction, Eltel’s core business in Poland will comprise fibre roll outs and mobile operations within Communication as well as design and build of overhead lines and substations within Power. These operations employ a total of approximately 1,000 people. For further information:Håkan KirsteinPresident and CEOTel: +46 8 585 376 00, hakan.kirstein@eltelnetworks.se About EltelEltel is a leading Northern European provider of technical services for critical infrastructure networks – Infranets – in the segments of Power, Communication and Other, with operations throughout the Nordics, Poland and Germany. Eltel provides a broad and integrated range of services, spanning from maintenance and upgrade services to project deliveries. Eltel has a diverse contract portfolio and a loyal and growing customer base of large network owners. In 2016, Eltel net sales amounted to EUR 1.4 billion. The current number of employees is approximately 9,500. Since February 2015, Eltel AB is listed on Nasdaq Stockholm.

World’s smallest fuel cell charger now even smaller: JAQ Hybrid from myFC debuts at Mobile World Congress Shanghai

Fuel cell charger JAQ Hybrid can both produce and store energy, which gives users complete flexibility and true mobility. It is charged either with myFC’s patented fuel card, using salt and water to produce hydrogen, or through a regular power outlet, depending on access and preference. “With JAQ Hybrid we’ve made the world’s smallest fuel cell charger even smaller and smarter. It’s a big step toward our vision of constantly available green energy. We at myFC are convinced that hybrids are the future of the power bank market, and we aim to lead that development,” says Björn Westerholm, CEO at myFC. JAQ Hybrid is designed by award-winning design agency Aruliden, and will initially be available in three colors: the signature JAQ purple, white/gold, and charcoal black. It delivers an output power of 10.5 W, capacity of 4,000 mAh, and weighs about 200 g. Each card is 1,250 mAh. As the charger can store energy, multiple cards can be used to charge several devices. A power card of 2,500 mAh will be introduced later, using the same standardized interface. JAQ Hybrid is fully compatible with Android and Apple iOS smartphones, tablets and USB 5V devices. It is compliant with international air safety regulations. JAQ Hybrid will be on display at Mobile World Congress Shanghai, June 28-30 at the New International Expo Center, Innovation City, Hall W3, Booth A05.  This information is information that myFC is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 01:55 CET on 28 of June 2017.

ExpreS2ion repositions and gains important ground in the fight against cancer through joint venture

AdaptVac now holds a prototype of breast cancer vaccine AdaptVac, a joint venture between ExpreS2ion and NextGen Vaccines ApS (NextGen), is dedicated to become a world leading player in the development of highly competitive vaccines and therapeutics for cancer, infectious diseases and immunological disorders. AdaptVac is a 50:50% joint venture between NextGen and ExpreS2ion and will operate as an independent business unit with costs and profits divided equally between the owners. Initially, AdaptVac will focus on two lead projects within oncology and infectious diseases, respectively. This is based on already established studies performed with the licensed VLP technology, where results have demonstrated safety and efficacy in established animal cancer models, leading to a prototype of a breast cancer vaccine. The second indication is not yet disclosed due to patent considerations, but its market value is in the same range as breast cancer. ExpreS2ion repositions and gains substantial economic boost CEO Dr. Steen Klysner says: “We expect to create substantial value for ExpreS2ion and its shareholders through the AdaptVac joint venture based on its superior technology platform and a high value pipeline. This joint venture represents a new market focus for ExpreS2ion and a strong repositioning potential, as we move from being mainly a service provider to also being a developer of vaccines. Based on the impressive existing results, I am certain that the therapeutic and prophylactic vaccines from AdaptVac will be important value drivers for the company in the future.”  Strong market potential and value Breast cancer is a widespread oncology indication affecting more than 1.3 million worldwide annually and resulting in more than 450,000 deaths (Tao, 2015: www.ncbi.nlm.nih.gov/pubmed/25543329). The most common treatment today is based on monoclonal antibodies, where the dominating therapy HERCEPTIN (trastuzumab) on an annual basis generates global sales of US$ 7 billion. While the decade long leadership by HERCEPTIN is expected to come to a halt in light of patent expiries and the introduction of biosimilars, the product profile of AdaptVac’s lead pipeline candidate has the potential to capture market shares, leading to significant sales levels. ExpreS2ion’s Board of Directors estimates a risk-adjusted net present value (rNPV) of AdaptVac’s two lead projects to be more than 100 mio SEK. The value of the rNPV represents the value from forecasted income from milestone payments and royalties of net sales based on an assessment of projected market size, costs for bringing the product to market, and taking into account the risk associated with currently being in the preclinical development stage.  Certified Adviser Sedermera Fondkommission is appointed as Certified Adviser for ExpreS2ion.

Halton’s kitchen solutions for 13 cruise ships on Meyer's shipyards in Germany and Finland

Halton’s advantages are the quality and energy-efficiency of their systems, and delivery process management from hood and air volume planning to implementation. Professional kitchens are generally extremely demanding environments in terms of indoor air temperature, humidity, and cooking emissions conditions. In addition, reliability, fire safety, and hygiene are emphasised in a cruise ship environment. - We are developing and testing our solution in close collaboration with the customer. We are also putting Halton’s exceptionally extensive expertise on demanding indoor air environments to use for developing new solutions for our customers, says Tommi Rantanen, the executive responsible for Halton Marine's operations. Halton provides the world’s widest range of indoor air solutions for demanding special environments from professional kitchens and ships to energy production environments, health care and laboratories, as well as demanding public buildings and workspaces. Halton is the global market leader in galley ventilation solutions, as well as fire dampers, for ocean cruise ships. The company also manufactures state-of-the-art solutions for cabin ventilation. ”We have established our position in several international shipyards. With the deal signed now and the hood deliveries included in it we are further strengthening our market position with cruise ships”, says Rantanen. The contract with MAC Hamburg was signed in November 2016. Deliveries for the first project begin in the autumn of 2017. The deliveries, along with their options, are worth over 10M€.

SSAB, LKAB and Vattenfall form joint venture company for fossil-free steel

“HYBRIT is a very important initiative for SSAB and a fossil-free Sweden by 2045. A joint venture company will enable us to work together effectively to eliminate the root cause of carbon dioxide emissions in the steel industry," said Martin Lindqvist, President and CEO of SSAB. "Our establishment of a joint venture to develop HYBRIT indicates our conviction that it is possible to develop a fossil-free production chain all the way from the mine to the steelworks. If we're successful, this will be a technology breakthrough that can make a global contribution to significantly limiting climate change," said Jan Moström, President and CEO of LKAB. "By taking this step, we are making clear our activities and determination to find solutions to the climate issue. Vattenfall can see that electrification of the industry and climate-smart hydrogen gas have an important role to play," says Magnus Hall, President and CEO of Vattenfall. As a result of forming the joint venture company, a recruitment process is under way to appoint a CEO. The Board of Directors comprises Martin Pei, chairman, Åsa Sundqvist, member, Andreas Regnell, member and Olle Wijk, non-voting member Last spring, SSAB, LKAB and Vattenfall launched an initiative to solve the carbon dioxide issue in the Swedish steel industry. By replacing today's blast furnace process that uses coal and coke with a process based on hydrogen gas, the aim is to develop a process that emits water rather than carbon dioxide. Since its launch, the initiative has received various support from the Swedish Energy Agency, including funding towards a four-year research project. This initiative is divided into three phases: a preliminary study up to the end of 2017, followed by research and pilot plant trials up to 2024. Finally, up to 2035 the plan is to perform trials in a full-scale demonstration facility. Sweden is uniquely qualified to undertake this initiative. It has a specialized and innovative steel industry, access to climate-smart and renewable electrical power, and the best-quality iron ore in Europe. To achieve this project, however, significant national contributions are still required from the state, research institutions and universities. On July 5, 2017, a debate on HYBRIT will be held in Almedalen. The topic is "Concern for the climate – solutions exist, but perhaps not where you think". Presenters include Martin Pei, CTO, SSAB, Jan Moström, President and CEO, LKAB, and Magnus Hall, President and CEO, Vattenfall. Venue: Dagens Nyheters Arena at Visby Strand at 14.15-15.00. You can also view the debate live on facebook.com/ssab.ab

Norsk Tipping AS signs a new agreement with Link Mobility AS on mobile communications.

Norsk Tipping has chosen Link Mobility as its mobile communications partner. Link Mobility was given the contract through an open tender competition and the agreement is valid for two years, with the option of renewal for another two years.Norsk Tipping is a government-owned limited company under the direction of the Norwegian Ministry of Culture. The company is assigned by the government to offer games that create excitement and entertainment within responsible limits, with the profits going to good causes. Norsk Tipping has more than 2 million customers and hade over NOK 32 billion in revenue for 2016. All profit from the gaming are distributed between sports, culture and humanitarian / social organizations according to a separate distribution key set by its owner, The Norwegian Government."Norsk Tipping is, after our experience, the first Norwegian company to have conducted a multi-channel tender offering. With this, Norsk Tipping shows that they have a clear mobile strategy that they want to communicate through the channels their customers use and prefer to communicate on, young as old. In addition to SMS, most people use and prefer channels like Facebook Messenger, WhatsApp, E-mail, MMS, App push and Snapchat as a communication platform. In additional to these there will always come new channels like RCS, Joyn, etc.            Link Mobility will at all time provide and deliver on all new channels that Norsk Tipping and other customers would like to use. "Says Ina Rasmussen, Director of LINK Mobility AS "Link Mobility delivered the most economically advantageous offer and won the tender competition among a number of sharp competitors. Communication with customers is very important to us and we are looking forward to working closely with Link Mobility over the next years," says Marit Skaugen Holmberg, Categorical Purchasing in Norsk Tipping AS.LINK Mobility are one of Europe's largest providers of B2C mobile services with a range of solutions for efficient and targeted mobile communications between businesses and their customers. LINK Mobility's parent company LINK Mobility Group ASA is listed on Oslo Stock Exchange."We are of course very happy and proud that Norsk Tipping has chosen LINK Mobility as its supplier and partner in their future mobile communications strategy, we are looking forward to a close and innovative cooperation for many years to come." Says Ina Rasmussen. For further information:  LINK Mobility AS                                Jan Tore Kjær, Director Marketing & Salesjan.tore.kjar@linkmobility.comCell: + 47 9595 3000

SSAB, LKAB and Vattenfall form joint venture company for fossil-free steel

“HYBRIT is a very important initiative for SSAB and a fossil-free Sweden by 2045. A joint venture company will enable us to work together effectively to eliminate the root cause of carbon dioxide emissions in the steel industry," said Martin Lindqvist, President and CEO of SSAB. "Our establishment of a joint venture to develop HYBRIT indicates our conviction that it is possible to develop a fossil-free production chain all the way from the mine to the steelworks. If we're successful, this will be a technology breakthrough that can make a global contribution to significantly limiting climate change," said Jan Moström, President and CEO of LKAB. "By taking this step, we are making clear our activities and determination to find solutions to the climate issue. Vattenfall can see that electrification of the industry and climate-smart hydrogen gas have an important role to play," says Magnus Hall, President and CEO of Vattenfall.  As a result of forming the joint venture company, a recruitment process is under way to appoint a CEO. The Board of Directors comprises Martin Pei, chairman, Åsa Sundqvist, member, Andreas Regnell, member and Olle Wijk, non-voting member Last spring, SSAB, LKAB and Vattenfall launched an initiative to solve the carbon dioxide issue in the Swedish steel industry. By replacing today's blast furnace process that uses coal and coke with a process based on hydrogen gas, the aim is to develop a process that emits water rather than carbon dioxide. Since its launch, the initiative has received various support from the Swedish Energy Agency, including funding towards a four-year research project. This initiative is divided into three phases: a preliminary study up to the end of 2017, followed by research and pilot plant trials up to 2024. Finally, up to 2035 the plan is to perform trials in a full-scale demonstration facility. Sweden is uniquely qualified to undertake this initiative. It has a specialized and innovative steel industry, access to climate-smart and renewable electrical power, and the best-quality iron ore in Europe. To achieve this project, however, significant national contributions are still required from the state, research institutions and universities. On July 5, 2017, a debate on HYBRIT will be held in Almedalen. The topic is "Concern for the climate – solutions exist, but perhaps not where you think". Presenters include Martin Pei, CTO, SSAB, Jan Moström, President and CEO, LKAB, and Magnus Hall, President and CEO, Vattenfall. Venue: Dagens Nyheters Arena at Visby Strand at 14.15-15.00. You can also view the debate live on facebook.com/ssab.ab "HYBRIT – the way to fossil-free steel" is a Joint Venture company between SSAB, LKAB and Vattenfall. By replacing coke and coal with hydrogen gas in steelmaking, the ambition is to achieve a process that discharges water, rather than carbon dioxide. This initiative was announced in the spring of 2016 and a Joint Venture company was formed one year later. Research will take place up to 2035. If this initiative is successful, HYBRIT will make a major contribution to a fossil-free Sweden." Contact:  Viktoria Karsberg, SSAB viktoria.karsberg@ssab.com +46 72 233 52 88 Bo Krogvig, LKAB bo.krogvig@lkab.com, +46 70 867 32 50 Magnus Kryssare,Vattenfall magnus.kryssare@vattenfall.com +46 76 769 56 07

SSAB, LKAB and Vattenfall form joint venture company for fossil-free steel

“HYBRIT is a very important initiative for SSAB and a fossil-free Sweden by 2045. A joint venture company will enable us to work together effectively to eliminate the root cause of carbon dioxide emissions in the steel industry," said Martin Lindqvist, President and CEO of SSAB. "Our establishment of a joint venture to develop HYBRIT indicates our conviction that it is possible to develop a fossil-free production chain all the way from the mine to the steelworks. If we're successful, this will be a technology breakthrough that can make a global contribution to significantly limiting climate change," said Jan Moström, President and CEO of LKAB.  "By taking this step, we are making clear our activities and determination to find solutions to the climate issue. Vattenfall can see that electrification of the industry and climate-smart hydrogen gas have an important role to play," says Magnus Hall, President and CEO of Vattenfall.  As a result of forming the joint venture company, a recruitment process is under way to appoint a CEO. The Board of Directors comprises Martin Pei, chairman, Åsa Sundqvist, member, Andreas Regnell, member and Olle Wijk, non-voting member Last spring, SSAB, LKAB and Vattenfall launched an initiative to solve the carbon dioxide issue in the Swedish steel industry. By replacing today's blast furnace process that uses coal and coke with a process based on hydrogen gas, the aim is to develop a process that emits water rather than carbon dioxide. Since its launch, the initiative has received various support from the Swedish Energy Agency, including funding towards a four-year research project. This initiative is divided into three phases: a preliminary study up to the end of 2017, followed by research and pilot plant trials up to 2024. Finally, up to 2035 the plan is to perform trials in a full-scale demonstration facility. Sweden is uniquely qualified to undertake this initiative. It has a specialized and innovative steel industry, access to climate-smart and renewable electrical power, and the best-quality iron ore in Europe. To achieve this project, however, significant national contributions are still required from the state, research institutions and universities. On July 5, 2017, a debate on HYBRIT will be held in Almedalen. The topic is "Concern for the climate – solutions exist, but perhaps not where you think". Presenters include Martin Pei, CTO, SSAB, Jan Moström, President and CEO, LKAB, and Magnus Hall, President and CEO, Vattenfall. Venue: Dagens Nyheters Arena at Visby Strand at 14.15-15.00. You can also view the debate live on facebook.com/ssab.ab "HYBRIT – the way to fossil-free steel" is a Joint Venture company between SSAB, LKAB and Vattenfall. By replacing coke and coal with hydrogen gas in steelmaking, the ambition is to achieve a process that discharges water, rather than carbon dioxide. This initiative was announced in the spring of 2016 and a Joint Venture company was formed one year later. Research will take place up to 2035. If this initiative is successful, HYBRIT will make a major contribution to a fossil-free Sweden."

Immunovia establishes US headquarters, including CLIA reference laboratory, in Boston

A highly skilled team with a proven track record of successfully establishing and scaling up CLIA accredited reference laboratories based on ground breaking new technologies have been recruited to carry out the US market first introduction, in the second half of 2018. Mats Grahn, CEO Immunovia, comments: “The market introduction of IMMrayTMPanCan –d, our blood based test for earlier detection of pancreas cancer, is the main focus for Immunovia. We have therefore chosen to establish our USA operations headquarters in Boston, which is the major biotech hub in the world. A very experienced laboratory team will be moving into Immunovia´s own reference laboratory that will cover Eastern USA, adding to our commercial group that will also be located at the Boston facilities. This East coast laboratory complements the existing collaboration we have with Knight Diagnostic Laboratories in Portland, serving Western USA. I consider this an important stepping stone in our US commercialization strategy.” For more information, please contact:Mats GrahnChief Executive Officer, CEO, ImmunoviaTel.: +46-70-5320230Email: mats.grahn@immunovia.com About ImmunoviaImmunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com) This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above. Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com. About CLIAThe Clinical Laboratory Improvement Amendments (CLIA) regulate laboratory testing and require clinical laboratories to be certificated by their state as well as the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing. Laboratories can obtain multiple types of CLIA certificates, based on the kinds of diagnostic tests they conduct. ### 

SenzaGen signs global distribution agreement with Charles River Laboratories

GARDskin is a genome-based test that – with higher accuracy than the current gold standard test method – reveals whether chemical substances are at risk of causing allergies.   "With this new global distribution agreement, we are linking up with yet another very strong partner for the global launch of GARDskin. Charles River is a leading player in many important geographical markets and in several different industries, and we are looking forward to working together in the commercialization of SenzaGen’s high performing, accurate allergy test," says SenzaGen CEO Anki Malmborg Hager. Charles River Laboratories International, Inc. is a global company that specializes in a range of preclinical laboratory services for the pharmaceutical and biotechnology industries. Among its customers are many of the world's leading pharmaceutical and biotechnology companies, academic institutions and government research centres. The company has more than 11,000 employees worldwide and is listed on the NYSE. For more information Anki Malmborg Hager, CEO, SenzaGen ABEmail: anki.malmborg.hager@senzagen.comTelephone: +46 768 284822 About GARDGARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have up to 90% reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen's tests are also capable of measuring the potency of a substance's allergenic properties. Consequently GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods. About SenzaGenSenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company's patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com 

Additional energy companies join SaltX pilot project - Göteborg Energi and Öresundskraft participate in testing of large-scale energy storage concept

As previously announced, the pilot project will be conducted with leading Swedish energy companies, the research- and knowledge company Energiforsk, technical consultant Sweco and Stockholm University. "The fact that Göteborg Energi and Öresundskraft also participate in the pilot project shows the interest energy companies have in large-scale energy storage and EnerStore. It is important for us to have several energy companies that can contribute with their respective expertise and perspectives. In addition, this broad participation allows for a good dissemination of SaltX worldwide patented energy storage technology," said Karl Bohman, CEO of SaltX Technology. Although Vattenfall hosts the pilot plant, Göteborg Energi and Öresundskraft will actively participate in the pilot project and contribute knowledge and information on the design, construction and evaluation of the pilot plant. Both Göteborg Energi and Öresundskraft will also participate in the SaltX application to the Swedish Energy Agency for external funding. For further information, please contact: Karl Bohman, CEO SaltX Technology, tel: 070 560 02 68 About Göteborg Energi Göteborg Energi - www.goteborgenergi.se – is owned by the city of Gothenburg, and one of Sweden's leading energy company offering electricity and power, district heating, gas, cooling, energy services and urban fiber. About Öresundskraft Öresundskraft - www.oresundskraft.se – is owned by the city of Helsingborg and has approximately 260,000 customers in northwestern Skåne. Öresundskraft provides district heating, electricity and district cooling to gas, broadband and services. About SaltX and EnerStore SaltX has developed and patented a Nano-Coated Salt (NCS) energy storage technology that is applied in the SaltX business area for large-scale energy storage for heat and power generation - EnerStore. By coating the SaltX material with different forms of nanoparticles, more energy can be stored in the salt and corrosion is prevented. The material entails high capacity to store intermittent energy sources such as wind and solar energy, with minimal storage losses and in a cost-effective manner.

Kungsleden strengthens in Finance, HR and IT

Peter Anderson has recently assumed the role as Head of Finance with the overall responsibility for accounting, reporting and financial management. Peter has many years of experience as CFO in various real estate companies e.g. Steen & Ström. Upon recently he held the position as CFO of ICA Fastigheter. The Finance department has also been reinforced by Linda Frölén who has assumed the role as Head of Financal Control with responsibility for consolidation and group accounting. Prior to joining Kungsleden, Linda worked with group accounting at the pharmaceutical company Meda. Furthermore, Kungsleden has recruited Hanna Brandström as HR Director. Hanna has approximately ten years of experience from working in the HR field. Her most recent employment was with SC Motors Sweden, holding the role as General Manager for their HR & Legal department.  In order to ensure the ambition of being in the forefront of the digitalization era, Maria Masuch was recruited this winter as Head of IT. Maria is in charge of Kungsleden’s strategic digitalization and IT transformation. She has a solid IT experience, most recently from SPP. Maria has also worked at Trygg-Hansa and as an IT and management consultant in several global organisations. -       We are very proud and happy to welcome these highly competent and professional people to our organisation. Both Peter, Linda, Hanna and Maria hold key positions within the company and have already started to create an increasingly effective and successful Kungsleden, says CEO Biljana Pehrsson.

Finnair awarded Future Travel Experience Ancillary Gold Award for making ancillary services available across its digital channels

Finnair has been awarded with Future Travel Experience Ancillary Gold Award for its ancillary offering and makings its ancillary offering available for customers across its digital channels. Finnair ancillary services can be bought through its booking engine at Finnair.com, through the Finnair mobile app, as well as through the Nordic Sky Wi-Fi portal available on Finnair’s long haul flights. The award was given at the Future Travel Experience industry event in Dublin on Monday. Finnair offers a wide range of ancillary services that customers can use to tailor their travel experience: customers can book their ride to the airport and back already when making their flight reservation, upgrade their travel class, pre-order inflight meals, reserve seats, pay for additional baggage and buy various destination services. The share of ancillaries in Finnair sales has increased steadily. “We want to offer services that improve the customers’ travel experience and add comfort. Ancillary services enable everyone to tailor their trip, for example by adding travel comfort or booking a transportation to the airport. We these new services together with our customers and our personnel, aiming to continuously improve the offering,” says Sari Nevanlinna, Head of Ancillary Business at Finnair. Finnair targets to nearly double its 2016 ancillary revenues by 2020. 

Saab Receives Order for NLAW

The order includes the supply of NLAW weapon systems, associated training equipment, such as drill rounds, indoor training simulators, and support and maintenance of the training equipment. Under a framework contract between Saab and armasuisse, orders can be placed for NLAW weapon systems and equipment during the period 2017-2030. “The Swiss customer has conducted a detailed, competitive evaluation incorporating both theoretical analyses and live firing tests, and we are proud to be able to say that NLAW came out as the winner. This order, as well as the framework contract, reaffirms NLAW’s capabilities against the threat from modern main battle tanks and armoured vehicles on today’s battlefield”, says Görgen Johansson, head of Saab business area Dynamics. NLAW is a shoulder-launched, anti-tank missile system that attacks the tank from above. The NLAW system combines the simplicity of light anti-armour weapons with the advantages of heavy, crew-operated guided missile systems. With NLAW, a single soldier can destroy a heavily protected modern Main Battle Tank with only one shot at a range from 20 to 800 metres. For further information, please contact: Saab Press Centre Ann Wolgers, Press Officer +46 (0)734 180 018 presscentre@saabgroup.com www.saabgroup.com  www.saabgroup.com/YouTube  Follow us on twitter: @saab  Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs.  The information is such that Saab AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 28 June 2017 at 10.00 (CET).

Skanska expands S:t Görans Hospital in Stockholm, Sweden, for about SEK 1.3 billion

The project includes rebuilding of existing hospital buildings and two completely new buildings that will contain facilities for care and treatment, delivery and reception. The preliminary size is about 29,000 square meters of new construction and about 5,000 square meters of conversion. The refurbished and new buildings will increase the capacity with about 6,000 visits, which corresponds to an extension of 62 ward units, and S:t Göran will also accommodate a new maternity department in a new building with room for 4,000 deliveries. The capacity for acute patients increases from 79,000 to 100,000 visits and the hospital receives an expanded mission in planned care, for example in neurology, infection, pulmonary medicine and urology as well as breast cancer care. The intention is that the rebuilt and newly constructed buildings at S:t Göran will be certified according to Miljöbyggnad, a certification for new and existing buildings focusing on energy, indoor environment and materials. The environmental classification system Miljöbyggnad is administered by the Swedish Green Building Council. Preparatory work began in the first quarter 2017 and the project is scheduled to be completed during the fourth quarter 2020. Skanska is one of the leading development and construction companies in the Nordics, with operations in building construction and civil engineering in Sweden, Norway and Finland, and developing residential- and commercial property projects in select home markets. The commercial development stream is also active in Denmark. Skanska offers services in public-private partnerships. Skanska had sales of about SEK 67 billion and more than 15,000 employees in its Nordic operations during 2016.

Trimb acquires well-established OTC products in Europe

Stockholm, June 28th 2017 – Trimb Healthcare AB (“Trimb”) has acquired a portfolio of well-established European OTC products from Cilag GmbH International and Janssen Pharmaceutica NV (collectively, “J&J”). The products, which include Pevaryl®, Fungoral®, Gyno-Pevaryl® and Epi-Pevaryl®, are based on the anti-fungal substances econazole and ketoconazole and are used to treat common fungal infections of the skin. The acquired territory includes Sweden, Norway, Germany, Switzerland, Austria and other European countries.“This deal with J&J is an important step for Trimb and we continue to strengthen our OTC position in northern Europe. We also strengthen our position in dermatology and we see good synergies with Trimb’s other anti-fungal brands, e.g. Cortimyk® and Nailner®”, said Magnus Kamryd, CEO of Trimb.The purchase price, which was not disclosed, was fully underwritten by Trimb’s lead investor, Avista Capital Partners, a leading private equity firm, and by CVC Credit Partners, the credit management business of CVC.For more information, please contact: Anders Larnholt, VP M&A Trimb     Email:      anders.larnholt@trimb.se Phone:     +46 76 677 64 95 Trimb Healthcare ABTrimb is a rapidly growing OTC and consumer healthcare company based in Stockholm, Sweden. The company’s experience and competencies span across all regulatory classes and most therapy fields relevant to consumer healthcare. Trimb’s products are sold in more than 50 countries and the company has its own go-to-market organization in northern Europe.

Citycon Oyj: Notification of change in holdings under chapter 9, section 5 of the Finnish Securities Market Act

Citycon Oyj has received a notification from Alecta pensionsförsäkring, ömsesidigt (Swedish business ID 502014-6865) on 28 June 2017, pursuant to Chapter 9, Section 5 of the Finnish Securities Markets Act.According to the notification, Alecta pensionsförsäkring, ömsesidigt’s holding of shares and voting rights in Citycon Oyj has exceeded the threshold of five (5) per cent on 27 June 2017.Total position of Alecta pensionsförsäkring, ömsesidigt subject to the notification: +----------------------------------+-----------+-----+----------------------+| |% of shares|Total|Total number of shares|| |and voting |in % |and voting rights of || |rights | |issuer |+----------------------------------+-----------+-----+----------------------+|Resulting situation on the date on|5.10 |5.10 |45,375,000 ||which the threshold was crossed or| | | ||reached | | | |+----------------------------------+-----------+-----+----------------------+ Notified details of the resulting situation on the date on which the threshold was crossed or reached:Shares and voting rights +------------+----------+-------------+------+--------------------------+|Class/type |Number of |% of ||of shares |shares and |shares ||ISIN code |voting |and || |rights |voting || | |rights |+------------+----------+-------------+------+--------------------------+| |Direct |Indirect (SMA|Direct|Indirect (SMA 9:6 and 9:7)|| |(SMA 9:5) |9:6 and 9:7) |(SMA | || | | |9:5) | |+------------+----------+-------------+------+--------------------------+|FI0009002471|45,375,000| |5.10 | |+------------+----------+-------------+------+--------------------------+|Subtotal |45,375,000| |5.10 | |+------------+----------+-------------+------+--------------------------+ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.CITYCON OYJEero Sihvonen, Executive Vice President and CFOTel. +358 50 557 9137eero.sihvonen@citycon.comHenrica GinströmVice President, Investor Relations and CommunicationsTel. +358 50 554 4296henrica.ginstrom@citycon.com Citycon Oyj (Nasdaq Helsinki: CTY1S) is a leading owner, developer and manager of urban grocery-anchored shopping centres in the Nordic and Baltic regions, managing assets that total approximately EUR 5 billion and with market capitalisation of EUR 2 billion. For more information about Citycon, please visit www.citycon.com

KappAhl Q3 2016/2017: Another good quarter

· Sales increased during the quarter by 1.8 per cent and in September-May by 5.5 per cent.  · The gross margin was 63.7 (64.9) and was negatively impacted by a higher percentage of clearance sales, changes in the range mix and a continued weak krona compared with the previous year.  · Operating profit for the quarter was SEK 119 (103) million and SEK 310 (251) million for September-May.   · The equity ratio is 65.7 (57.3) per cent.  · Growth over the rolling twelve months is 6.3 per cent.  After the end of the quarter · KappAhl have decided to open Newbie Store and associated online shopping in the United Kingdom. The first stores are expected to open during the fall. Third Nine month  (Sep-May) Quarter (Mar -May)  2016/201 2015/ Change 2016/2017 2015/2016 Change 7 2016    Net sales, SEK million 1 217 1 195 22 3 668 3 476 192 Operating profit/loss, 119 103 16 310 251 59SEK millionGross margin, % 63,7 64,9 -1,2 62,7 63,1 -0,4Operating margin, % 9,8 8,6 1,2 8,5 7,2 1,3Profit after tax, SEK 81 89 -8 222 186 36millionEarnings per share, SEK 1,05 1,16 -0,11 2,89 2,42 0,47Cash flow from operating 322 202 120 511 307 204activities, SEK million This information is information that KappAhl AB is obliged to disclose pursuant to the EU Market Abuse  Regulation and the Securities Market Act. The information was released for public disclosure through the agency of President and CEO Danny Feltmann on 29 June 2017 at 07.30 CET. 

ASSA ABLOY acquires Atlantic Door Control in the U.S.

ASSA ABLOY has acquired Atlantic Door Control, a pedestrian door distributor in Maryland and Virginia."I am very pleased that Atlantic Door Control is joining the ASSA ABLOY Group. I welcome this addition that further reinforces ASSA ABLOY’s leadership in entrance automation, where our sales have grown from SEK 3 billion in 2008 to SEK 20 billion in 2016”, says Johan Molin, President and CEO of ASSA ABLOY.“We hereby continue our expansion in North America, adding to our growing market footprint. Atlantic Door Control gives us a strong presence in an important area of the market and I welcome the team to ASSA ABLOY,” says Juan Vargues, Executive Vice President of ASSA ABLOY and Head of Division Entrance Systems.Atlantic Door Control was established in 1992 and the company is headquartered in Columbia, Maryland.Sales for 2017 are expected to reach USD 12 million (approx. SEK 110 million) with a good EBIT margin. The acquisition will be accretive to EPS from start.  For more information, please contact:Johan Molin, President and CEO, tel. no: +46 8 506 485 42Carolina Dybeck Happe, CFO and Executive Vice President, tel. no: +46 8 506 485 72 About ASSA ABLOYASSA ABLOY is the global leader in door opening solutions, dedicated to satisfying end user needs for security, safety and convenience. Since its formation in 1994, ASSA ABLOY has grown from a regional company into an international group with about 47,000 employees, operations in more than 70 countries and sales of SEK 71 billion. In the fast-growing electromechanical security segment, the Group has a leading position in areas such as access control, identification technology, entrance automation and hotel security.

H & M Hennes & Mauritz AB Six-month report

First half-year (1 December 2016 – 31 May 2017) · The H&M group’s sales including VAT increased by 9 percent to SEK 113,907 m (104,965) during the first six months of the financial year. Sales excluding VAT amounted to SEK 98,368 m (90,565). In local currencies sales increased by 5 percent. · Profit after financial items increased by 6 percent to SEK 10,920 m (10,329). The group’s profit after tax amounted to SEK 8,354 m (7,902), corresponding to SEK 5.05 (4.77) per share. Second quarter (1 March 2017 – 31 May 2017)   · The H&M group’s sales including VAT increased by 10 percent to SEK 59,538 m (54,341) during the second quarter. Sales excluding VAT amounted to SEK 51,383 m (46,874). In local currencies sales increased by 5 percent. · Gross profit increased by 9 percent to SEK 29,345 (26,980). This corresponds to a gross margin of 57.1 percent (57.6). · Profit after financial items increased by 10 percent to SEK 7,708 m (7,002). The group’s profit after tax amounted to SEK 5,897 m (5,357), corresponding to SEK 3.56 (3.24) per share. The profit increase in the second quarter is mostly explained by continued expansion and tight cost control. · Continued rapid and profitable growth of the group’s online sales, which in some established markets already account for 25 to 30 percent of total sales. The profitability of the group’s online sales is in line with that of the physical stores. · H&M’s online store opened in further six new markets during the spring - Turkey, Taiwan, Hong Kong, Macau, Singapore and Malaysia – and is now available in 41 markets. · Continued very good development for COS, & Other Stories, Monki, Weekday and H&M Home. · The H&M group’s sales including VAT for June 2017 are expected to increase by 7 percent in local currencies compared to the same month last year. · Successful store openings in new H&M markets Kazakhstan and Colombia this spring will be followed by openings in Iceland, Vietnam and Georgia. · H&M’s online store will open in a further two markets in 2017 - the Philippines and Cyprus - in addition to the six online markets that have already opened in 2017. · COS will reach turnover of around SEK 10 billion in 2017, with profitability in line with that of the H&M brand. · The new brand, ARKET, will be launched in 2017 with five stores and 18 online markets. · Continued investments with a digital focus. It is estimated that the group’s online sales will grow by at least 25 percent per year going forward. · India will be a new H&M online market in 2018. Additional new online markets will open in 2018. · New H&M store markets planned for 2018 are Uruguay and Ukraine. Comments by Karl-Johan Persson, CEO“Sales in the second quarter increased by 10 percent in SEK to more than SEK 59 billion including VAT. In local currencies, sales increased by 5 percent. Profit after financial items increased by 10 percent to SEK 7.7 billion. Sales in the UK, Scandinavia and Eastern Europe as well as in many of our growth markets were good. However, it was more challenging in several of our major markets such as the US, China, the Netherlands and Switzerland. H&M’s online sales developed very well and continued to increase its share of total sales. The development of COS, & Other Stories, Monki, Weekday and H&M Home remained very strong, both in stores and online. An industry in transitionFashion retail is going through a period of extensive change because of increased digitalisation. Customer behaviour and expectations are changing at an ever-increasing pace, with a greater and greater share of sales taking place online. This shift brings great opportunities for the H&M group. We are in a strong position, with well-known global brands suited to both physical stores and online sales, and we are financially strong and can invest at the pace required. Continued investments and digital focusWe continue to invest and develop our business with a digital focus to give our customers the best possible shopping experience. This includes: · Improvement, diversification and expansion of our online offering – for example more and faster delivery options, more payment alternatives, a broader range of products and more new markets. · Integration of our physical stores with the online store – to offer a shopping experience where customers are always able to move freely between our various channels and shop in the way that suits them best. Our global store network gives us a unique proximity to our customers, which is a great asset and advantage. · Expansion of new physical stores with a focus on growth markets – around 500 new stores with very favourable conditions are planned to open during the year. · Optimisation and development of the store portfolio – rebuilds, relocations, additional store space. Around 100 store closures during the year. Development of H&M stores to include new forms of visual expression for a more inspiringin-store experience. · Supply chain optimisation – increased speed, efficiency and flexibility. · Advanced analytics – allows further improvements in areas such as the product range development, quantification, allocation and personalised communication. The ability to build new brands and conceptsAn important part of the H&M group’s strategy is to develop, launch and build new global brands. A good example of this is COS, which will reach revenues of around SEK 10 billion this year with profitability in line with that of the H&M brand. The value of COS today already far exceeds the amount we invested in it and this is just the beginning of the journey. Our other brands, & Other Stories, Monki, Weekday, Cheap Monday and H&M Home, are very well-positioned to make the same journey as COS. We are expecting our newer brands to continue to grow substantially for many years to come and to account for an increasing share of the H&M group’s growth and value. After the summer, we are looking forward to launching yet another new brand, ARKET, which received fantastic reviews at previews during the spring. The first store will open on Regent Street in London with the simultaneous launch of ARKET’s online store in 18 European markets. Continued rapid and profitable online growthThe H&M group’s online sales have developed very well and already account for 25 to 30 percent of total sales in certain established markets. We are expecting our online sales to increase by at least 25 percent per year, with profitability in line with that of the physical stores. Fast pace is vitalWe are convinced that the investments we have made and are making will result in continued profitable growth for many years to come. A clear focus for us is to continue to develop our business with quality at a fast pace and thereby strengthen the H&M group’s position even further in a growing and rapidly changing market.” ContactNils Vinge, IR +46 8 796 52 50Karl-Johan Persson, CEO +46 8 796 55 00 (switchboard)Jyrki Tervonen, CFO +46 8 796 55 00 (switchboard) Invitation to press and telephone conference in conjunction to the six-month report is available on about.hm.com H & M Hennes & Mauritz AB (publ)SE-106 38 StockholmPhone: +46-8-796 55 00, Fax: +46-8-24 80 78, E-mail: info@hm.comRegistered office: Stockholm, Reg. No. 556042-7220   Information in this interim report is that which H & M Hennes & Mauritz AB (publ) is required to disclose under EU Market Abuse Regulation (596/2014/EU) and Sweden’s Securities Market Act. The information was submitted for publication by the abovementioned persons at 8.00 (CET) on 29 June 2017. This interim report and other information about H&M, is available at about.hm.com H & M Hennes & Mauritz AB (publ) was founded in Sweden in 1947 and is quoted on Nasdaq Stockholm. H&M’s business idea is to offer fashion and quality at the best price in a sustainable way. In addition to H&M, the group includes the brands & Other Stories, Cheap Monday, COS, Monki and Weekday as well as H&M Home. The H&M group has 41 online markets and approximately 4,500 stores in 66 markets including franchise markets. In 2016, sales including VAT were SEK 223 billion. The number of employees amounts to more than 161,000. For further information, visit about.hm.com. 

Rikard Josefson named new CEO of Avanza

“Rikard has a deep knowledge of customers, technology and banking. Just like us at Avanza. That’s why we found each other so quickly and naturally,” said Sven Hagströmer, Chairman of the Board of Avanza. Rikard Josefson, 51, has served for the last six years as CEO of Länsförsäkringar Bank, where he, among other things, has helped to develop the bank’s mobile services, mortgage products and “savings robot”. At the same time, Länsförsäkringar, like Avanza, has won several awards for Sweden’s highest customer satisfaction. In addition Länsförsäkringar has won the best mobile app award. Previously, Rikard spent 25 years at SEB. “I am proud of my work at Länsförsäkringar, where we doubled business volumes during my time as CEO. Now I am excited to be a part of Avanza as it continues to challenge the banking market,” said Rikard Josefson. More on Rikard’s background follows below. “This information is such that Avanza Bank Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the contact person set out below, at 08:30 CEST on 29 June 2017." Summary of Rikard Josefson’s background: 2011 - 2017   Länsförsäkringar Bank, CEO 1986 - 2011   SEB. Most recently as Deputy Head of SEB’s Swedish retail banking operations. Regional Director for six years with responsibility for telephone and internet banking as well as development and sales.   Education:     B.A. in Economics from Stockholm University

Global manufacturer selects IFS Applications 9 to integrate key business processes

BIM Kemi is a rapidly growing global developer and manufacturer of concepts, technology and services for the pulp, paper, board and cellulose fiber industries. The company has offices in ten countries, including Finland, Norway, Germany, the UK, South Africa and Sweden. Following a thorough evaluation process, BIM Kemi chose IFS Applications 9 to enhance the efficiency of its multi-site business. The IFS solution includes support for key business processes, including financials, supply chain management, process manufacturing, sales and CRM as well as business intelligence. IFS Applications 9 will replace a number of legacy systems and point-to-point solutions to form the unifying ERP backbone for BIM Kemi. “By implementing a central ERP solution across our sales and manufacturing units we will be able to achieve significant efficiencies such as optimized productivity, quality and transparency,” said Stefan Krantz at BIM Kemi. “IFS Applications 9 stood out as the superior solution for unifying our business across the regions where we are active. We also found a good cultural fit with the IFS partner Novacura and we look forward to getting started on the roll-out together”. “IFS Applications is a good fit with the operations of BIM Kemi and the relationship between Novacura and BIM Kemi is excellent. Together we will establish a global platform for efficiency and future growth,” said Johan Melander, CEO at Novacura. Glenn Arnesen, CEO for IFS in Scandinavia, added, “We are very pleased that yet another successful, global manufacturer has chosen IFS. This is a great win for both IFS and our partner Novacura and a testament to the continued success of our partner strategy. The chemical and pulp and paper industries are part of IFS’s heritage and a strong area of expertise for us. BIM Kemi is a perfect example of how a rapidly growing global company can use IFS Applications to enhance business process efficiency across several regions to boost performance.” You can read more about IFS’s solutions for pulp and paper here: www.ifsworld.com/corp/industries/asset-intensive/pulp-and-paper-software/.

New Group Management Team appointed for the combined Intrum Justitia and Lindorff

The new Group Management Team of the combined Intrum Justitia and Lindorff has been appointed. “I am very pleased with the composition of this new management team. Each individual member possesses the expertise and management skills necessary to take this combined company to the next level and deliver on the promises that we have made to our stakeholders. It was important for me to find a balance, where both companies’ core strengths are being utilized in the new Group and I believe this team reflects this,” says Mikael Ericson, CEO & President of the combined company. The new management team, in addition to the CEO, consists of the following members: · Alejandro Zurbano, Regional Managing Director, Spain (RMD) · Anders Engdahl, Chief Investment Officer (CIO) · Anette Willumsen, Regional Managing Director, Northern Europe (RMD) · Anne Louise Eberhard, Chief Commercial Officer (CCO) · Annika Billberg, Chief Brand & Communications Officer (CBCO) · Cathrine Klouman, Chief Operating Officer (COO) · Erik Forsberg, Chief Financial Officer (CFO) · Harry Vranjes, Head of Project Management Office (PMO) · Jean-Luc Ferraton, Chief Human Resources Officer (CHRO) · Johan Brodin, Chief Risk Officer (CRO) · Marc Knothe, Regional Managing Director, Western & Southern Europe (RMD) · Niklas Lundquist, Chief Legal Officer (CLO) · Per Christofferson, Regional Managing Director Central & Eastern Europe (RMD) The combined company will be organized into the following four regions: · Northern Europe – Denmark, Estonia, Finland, Latvia, Lithuania, Norway, Sweden · Central & Eastern Europe – Austria, Czech Republic, Germany, Hungary, Poland, Romania, Slovakia, Switzerland · Western & Southern Europe – Belgium, France, Ireland, Italy, Netherlands, Portugal, United Kingdom · Spain For more information about the members of the senior management team, please visit intrum.com. This information was submitted for publication, through the agency of the contact person set out below, at 09.00 CET on June 29 2017. For further information, please contact:Mikael EricsonCEO & PresidentTel: +46 8 546 102 02 Annika BillbergChief Brand & Communications OfficerTel: + 46 702 67 97 91 About Intrum Justitia:Intrum Justitia offers comprehensive services, including purchase of receivables, designed to measurably improve clients’ cash flows and long-term profitability. Founded in 1923, Intrum Justitia has some 4,000 employees in 20 markets. Consolidated revenues amounted to SEK 6.1 billion in 2016. Intrum Justitia AB is listed on Nasdaq Stockholm since 2002. For further information, please visit www.intrum.com About Lindorff:Lindorff has been in the business of helping people manage credit for over 100 years. Its headquarters are located in Oslo, Norway, the same city where Eynar Lindorff founded the company back in 1898. Today it has 4,400 people in 12 countries across Europe helping customers back to a life of sustainable spending. Nordic Capital Fund VIII is a majority shareholder in the company which offers services within debt collection and debt purchase as well as payment and invoicing services. In 2016 Lindorff generated EUR 647 million in net revenue (2015 EUR 534 million). For further information, please visit www.lindorff.com 

Sedana Medical AB (publ) in final deal with Teleflex Medical Incorporation

Since the acquisition of AnaConDa technology by Teleflex in 2005, Sedana Medical has paid royalty on the sale of AnaConDa products. In connection with this deal, Sedana Medical pays a one-off amount of $ 750,000 instead of the remaining $ 1,051,000 of royalties, which means a significant saving. This means that Sedana Medical's all royalties and any other commitments with Teleflex have been terminated. Sedana Medical has thereby no royalty commitments to any party. “This agreement goes hand-in-hand with our strategy and ongoing efforts to independently develop the therapy inhalation sedation in intensive care, and the expand of our sales organisation. We have thanks to this agreement taken another step towards realising our vision of making inhalation sedation with IsoConDa and AnaConDa a global standard method for the sedation of mechanically ventilated patients in intensive care,” says Christer Ahlberg, CEO of Sedana Medical AB (publ). The market in brief Sedana Medical's market consists primarily of mechanically ventilated intensive care patients. The market for sedation of mechanically ventilated intensive care patients today consists of established drugs that are administered intravenously. The target group that the Company focuses on are those patients who are ventilated for more than 24 hours, a target group that globally amounts to between two and four million patients per year. In total, the Company consider this to be an addressable market of SEK 10-20 billion per year, of which Europe accounts for about SEK 6 billion. For additional information, please contact: Christer Ahlberg, CEO, Sedana Medical ABMobile: +46 70 675 33 30, E-mail: Christer.ahlberg@sedanamedical.com Pareto Securities is certified advisor to Sedana Medical. This information is such that Sedana Medical AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on 29 June 2017 at 09.00 a.m. (CET).

MR tanker Stena Impeccable named in Rotterdam

The Stena Impeccable was delivered at the beginning of March this year after which she sailed from China to Australia with a cargo of caustic soda. She then sailed with a cargo of vegetable oil from New Guinea via Singapore and the Suez Canal to Rotterdam. After the naming ceremony, the vessel left Rotterdam with Captain Vinay Singh at the helm for Brake in Germany where she will discharge the remainder of her cargo. “The Port of Rotterdam is the largest port in Europe and our fleet often calls there. That’s why we also have many business contacts in the area and we took the opportunity to gather them in conjunction with this naming ceremony”, said Erik Hånell, President and CEO of Stena Bulk. The Stena Impeccable was built at the Chinese shipyard GSI (Guangzhou Shipbuilding International) like all the 13 IMOIIMAX tankers ordered by Stena Bulk – both delivered and under construction. The vessel is wholly owned by Stena Bulk, operated by Stena Weco and sails in the company’s global logistics system, which currently employs around 60 vessels. Six of the 13 IMOIIMAX tankers are wholly owned by Stena Bulk, four together with GAR (Golden Agri Resources), two by Stena Bulk’s sister company Concordia Maritime and one in a partnership with Weco. Ten tankers have so far been delivered and the remaining three will be delivered by 2018. Facts - the IMOIIMAX concept IMOIIMAX is a further development of an already well-established concept and the innovative technical design was developed by Stena Teknik together with the Chinese shipyard GSI. It offers several advantages such as extra large cargo flexibility, a high level of safety and economical fuel consumption – 10-20% lower than that of equivalent vessels when sailing at service speed. Technical data: length: 183 metres, beam: 32 metres, deadweight: 50,000 tons. For further information, please contact: Erik HånellPresident & CEOStena Bulk ABMobile: +46 704 855 002erik.hanell@stenabulk.com  With offices in six countries, Stena Bulk is one of the world’s leading tanker shipping companies. The company controls a combined fleet of around 100 vessels. Stena Bulk is part of the Stena Sphere, which has more than 20,000 employees and sales of SEK 60 billion. www.stenabulk.comThe first photo to the left: Henk Roskamp, Managing Director RVB Shipbrokers, Frank Verbunt, Spouse to Godmother, Godmother Trijntje Margaretha Oosters of RVB Shipbrokers, Johnny Schmolker, Deputy Managing Director Stena Weco, Master of Stena Impeccable Vinay Singh, Erik Hånell, President & CEO Stena Bulk.